

7-12-01

JCOB Rec'd PCT/PTO 1 0 JUL 2001

09889236.050404

PCT

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE <b>TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371</b>		ATTORNEY'S DOCKET NUMBER <b>PF-0659 USN</b>
		U.S. APPLICATION NO. (if known, see 37 CFR 1.5) TO BE ASSIGNED <b>09/889236</b>
INTERNATIONAL APPLICATION NO. PCT/US00/01086	INTERNATIONAL FILING DATE 14 January 2000	PRIORITY DATE CLAIMED 15 January 1999
TITLE OF INVENTION <b>PROTEINS ASSOCIATED WITH CIRCADIAN RHYTHMS</b>		
APPLICANT(S) FOR DO/EO/US <b>INCYTE PHARMACEUTICALS, INC.; HILLMAN, Jennifer L.; TANG, Y. Tom; LU, Dyung Aina M.; AZIMZAI, Yalda</b>		
<p>Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:</p> <ol style="list-style-type: none"><li>1. <input checked="" type="checkbox"/> This is the <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.</li><li>2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.</li><li>3. <input type="checkbox"/> This is an express request to promptly begin national examination procedures (35 U.S.C. 371 (f)).</li><li>4. <input type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (PCT Article 31).</li><li>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))<ol style="list-style-type: none"><li>a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau)</li><li>b. <input type="checkbox"/> has been communicated by the International Bureau.</li><li>c. <input checked="" type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</li></ol></li><li>6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).</li><li>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))<ol style="list-style-type: none"><li>a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</li><li>b. <input type="checkbox"/> have been communicated by the International Bureau.</li><li>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</li><li>d. <input checked="" type="checkbox"/> have not been made and will not be made.</li></ol></li><li>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</li><li>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</li><li>10. <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</li></ol>		
<b>Items 11 to 16 below concern document(s) or information included:</b>		
<ol style="list-style-type: none"><li>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</li><li>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.27 and 3.31 is included.</li><li>13. <input type="checkbox"/> A <b>FIRST</b> preliminary amendment. <input type="checkbox"/> A <b>SECOND</b> or <b>SUBSEQUENT</b> preliminary amendment.</li><li>14. <input type="checkbox"/> A substitute specification.</li><li>15. <input type="checkbox"/> A change of power of attorney and/or address letter.</li><li>16. <input checked="" type="checkbox"/> Other items or information:<ol style="list-style-type: none"><li>1) Transmittal Letter (2 pp, in duplicate)</li><li>2) Return Postcard</li><li>3) Express Mail Label No.: <b>EL 856 154 282 US</b></li><li>4) Request to Transfer</li></ol></li></ol>		

09889236 050902

JC18 Rec'd PCT/PTO 1 0 JUL 2001

U.S. APPLICATION NO. (if known) <b>09/889236</b> TO BE ASSIGNED		INTERNATIONAL APPLICATION NO.: PCT/US00/01086		ATTORNEY'S DOCKET NUMBER PF-0659 USN	
17. <input type="checkbox"/> The following fees are submitted: <b>BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)):</b> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO.....\$1000.00 <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO...\$860.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO.....\$710.00 <input checked="" type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4).....\$690.00 <input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4).....\$100.00					
<b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>				\$690.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total Claims	23 =	3	X \$ 18.00	\$ 54.00	
Independent Claims	2 =	0	X \$ 80.00	\$	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$270.00	\$	
<b>TOTAL OF ABOVE CALCULATIONS =</b>				\$744.00	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$	
<b>SUBTOTAL =</b>				\$744.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	
<b>TOTAL NATIONAL FEE =</b>				\$744.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by the appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$	
<b>TOTAL FEES ENCLOSED =</b>				\$744.00	
				Amount to be Refunded:	\$
				Charged:	\$
a. <input type="checkbox"/> A check in the amount of \$ _____ to cover the above fees is enclosed. b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. <u>09-0108</u> in the amount of \$ <u>744.00</u> to cover the above fees. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>09-0108</u> . A duplicate copy of this sheet is enclosed.  <b>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must          be filed and granted to restore the application to pending status.</b>  SEND ALL CORRESPONDENCE TO:  INCYTE GENOMICS, INC. 3160 Porter Drive Palo Alto, CA 94304					
<div style="text-align: right; margin-right: 100px;">             SIGNATURE         </div> <div style="text-align: right; margin-right: 100px;">           NAME: Diana Hamlet-Cox         </div> <div style="text-align: right; margin-right: 100px;">           REGISTRATION NUMBER: 33,302         </div> <div style="text-align: right; margin-right: 100px;">           DATE: <u>10</u> July 2001         </div>					

**PROTEINS ASSOCIATED WITH CIRCADIAN RHYTHMS****TECHNICAL FIELD**

This invention relates to nucleic acid and amino acid sequences of proteins associated with  
5 circadian rhythms and to the use of these sequences in the diagnosis, treatment, and prevention of  
reproductive disorders, gastrointestinal disorders, neuronal disorders, and developmental disorders.

**BACKGROUND OF THE INVENTION**

The most important external cue for the brain which leads to the establishment of biological  
10 rhythms is light. Mammals tend to be either diurnal or nocturnal, dividing their periods of rest and  
activity along the lines corresponding to dawn and dusk. The dominant cycle of day and night is  
called the circadian rhythm. Circadian rhythmicity of biologic processes is a fundamental property of  
all eukaryotic and some prokaryotic organisms. These rhythms are driven by an internal time-keeping  
15 system. Changes in the external environment, particularly in the light-dark cycle, train this biologic  
clock. Under constant environmental conditions devoid of time cues, rhythms driven by the clock  
show a period near 24 hours. Although, when placed in sensory-deprived environments, mammals  
exhibit rhythms that approximate the 24 hour cycle, they differ from it to a greater or lesser degree  
according to species. Humans, for instance, exhibit rhythms that average about one hour longer than  
20 the usual 24 hour cycle. After a period of isolation from the usual time cues, most humans settle into  
a 25 hour period of rest and activity. However, some subjects shift into 48 to 50 hour cycles, twice  
the normal rhythm. The isolation from usual time cues can exert stresses on physical and mental  
health. In humans, the normal rhythms of wakefulness and sleep, centering around 24 hours, seem to  
exert a stabilizing effect on physical and psychological health. A disruption in this rhythm may come  
as a result of different body rhythms that break away from their usual synchrony and take on a new  
25 pattern. (Reviewed in Restak, R.M. (1984) The Brain, Bantam Books, New York NY, pp. 101-111.)

The suprachiasmatic nucleus (SCN) of the hypothalamus contains a master circadian clock  
that regulates most, if not all, circadian rhythms in mammals. Its name derives from the location of  
the SCN, just above the optic chiasm. The SCN receives information about light and dark from the  
eyes, but it has its own dedicated pathway of nerves, the retino-hypothalamic tract (RHT), which is  
30 separate from the main nerve bundles carrying visual information to the brain. When the SCN is  
destroyed in experimental animals by surgical pinpoint lesions of the brain, rhythms in sleep and  
wakefulness, and many other rhythms, fade away. Interestingly, animals lacking a SCN will run, eat  
and drink the same total amount each 24 hours, but these activities are now randomly distributed  
throughout the day and night. Melatonin, the principal hormone of the pineal gland, can alter the

timing of mammalian circadian rhythms. The circadian effects of melatonin appear to be mediated by melatonin receptors in the SCN.

Generally, less is known about the extent and character of circadian rhythm regulated gene expression. In Drosophila melanogaster, only the period (per) gene, an essential component of the circadian pacemaker, is known to show rhythmic mRNA expression. Evaluation of circadian control of gene expression in D. melanogaster has identified genes that are dependent on per for circadian expression such as the D. melanogaster rhythmically expressed gene 2 (Dreg-2). Certain mRNAs were found to be maximally expressed in the morning, whereas other mRNAs were found to be most abundantly expressed in the evening. Each "morning" cDNA was found to have a unique dependence on the presence of a light-dark cycle, on timed feeding, and on the function of the per gene for its oscillation. Consequently, diurnal control of gene expression is a significant phenomenon in the fly head, which involves many uncharacterized genes. A subset of circadianly expressed genes are predominantly dependent on per for their rhythmic expression (Van Gelder, R.N. et al. (1995) Curr. Biol. 5:1424-1436). Another interesting molecule involved in biological timing is the 187-residue CLK-1 protein, a product of the clk-1 gene. The activity of clk-1 in the nematode Caenorhabditis elegans controls the rate of the worm's development, the pace of its behaviors, and when it dies. In C. elegans clk-1 mutants, the timing of physiological processes is deregulated, suggesting the existence of a timing mechanism that influences timed processes throughout the worm's life. CLK-1 was found to be highly conserved among nematodes, rodents, and humans, and is structurally similar to the yeast metabolic regulator COQ7. Human, rat, and mouse homologs of the clk-1 gene are 33% identical over 177 residues. The level of identity between rat and human sequences strongly supports the notion of functional conservation of clk-1 from yeast to human. In addition, sequences of CLK-1 homologs can be split and aligned to reveal the presence of a tandemly repeated core (TRC) 82-residue domain with several conserved hydrophobic residues (Ewbank, J.J. et al. (1997) Science 275:980-983).

Seasonal affective disorder (SAD) is a form of recurrent depressive or bipolar disorder, with episodes that vary in severity. Patients with seasonal affective disorder (SAD) often have abnormalities in resetting their circadian clock. The most recognized form of seasonal affective disorder, "winter depression," is characterized by recurrent episodes of depression, hypersomnia, carbohydrate craving, and weight gain that begin in the autumn and continue through the winter months. Current research on SAD covers fields such as retinal deficiency, phase-disturbance of the internal circadian rhythms, and neuroendocrinologically expressed disorders, assuming that melatonin is the main mediator of human circadian systems in the CNS. Disorders of neurotransmitters such as serotonin have also been implicated in SAD. Among patients treated for depression, the prevalence of

SAD is even higher (Gysin, F. et al. (1997) Acta. Med. Port. 10:887-893).

The discovery of new proteins associated with circadian rhythms and the polynucleotides encoding them satisfies a need in the art by providing new compositions which are useful in the diagnosis, prevention, and treatment of reproductive disorders, gastrointestinal disorders, neuronal disorders, and developmental disorders.

### SUMMARY OF THE INVENTION

The invention features purified polypeptides, proteins associated with circadian rhythms, referred to collectively as "CIRYP" and individually as "CIRYP-1" and "CIRYP-2." In one aspect, the invention provides an isolated polypeptide comprising a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-2, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-2, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-2, or d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-2. In one alternative, the invention provides an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:1-2.

The invention further provides an isolated polynucleotide encoding a polypeptide comprising a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-2, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-2, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-2, or d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-2. In one alternative, the polynucleotide is selected from the group consisting of SEQ ID NO:3-4.

Additionally, the invention provides a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding a polypeptide comprising a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-2, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-2, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-2, or d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-2. In one alternative, the invention provides a cell transformed with the recombinant polynucleotide. In another alternative, the invention provides a transgenic organism comprising the recombinant polynucleotide.

The invention also provides a method for producing a polypeptide comprising a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-2, b) a naturally occurring amino

acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-2, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-2, or d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-2. The method comprises a)

5 culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding the polypeptide, and b) recovering the polypeptide so expressed.

Additionally, the invention provides an isolated antibody which specifically binds to a polypeptide comprising a) an amino acid sequence selected from the group consisting of SEQ ID

10 NO:1-2, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-2, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-2, or d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-2.

The invention further provides an isolated polynucleotide comprising a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:3-4, b) a naturally occurring polynucleotide sequence having at least 70% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:3-4, c) a polynucleotide sequence complementary to a), or

15 d) a polynucleotide sequence complementary to b). In one alternative, the polynucleotide comprises at least 60 contiguous nucleotides.

20

Additionally, the invention provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide comprising a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:3-4, b) a naturally occurring polynucleotide sequence having at least 70% sequence identity to a polynucleotide

25 sequence selected from the group consisting of SEQ ID NO:3-4, c) a polynucleotide sequence complementary to a), or d) a polynucleotide sequence complementary to b). The method comprises a) hybridizing the sample with a probe comprising at least 16 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed

30 between said probe and said target polynucleotide, and b) detecting the presence or absence of said hybridization complex, and optionally, if present, the amount thereof. In one alternative, the probe comprises at least 30 contiguous nucleotides. In another alternative, the probe comprises at least 60 contiguous nucleotides.

The invention further provides a pharmaceutical composition comprising an effective amount

of a polypeptide comprising a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-2, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-2, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-2, or d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-2, and a pharmaceutically acceptable excipient. The invention additionally provides a method of treating a disease or condition associated with decreased expression of functional CIRYP, comprising administering to a patient in need of such treatment the pharmaceutical composition.

The invention also provides a method for screening a compound for effectiveness as an agonist of a polypeptide comprising a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-2, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-2, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-2, or d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-2. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting agonist activity in the sample. In one alternative, the invention provides a pharmaceutical composition comprising an agonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with decreased expression of functional CIRYP, comprising administering to a patient in need of such treatment the pharmaceutical composition.

Additionally, the invention provides a method for screening a compound for effectiveness as an antagonist of a polypeptide comprising a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-2, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-2, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-2, or d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-2. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting antagonist activity in the sample. In one alternative, the invention provides a pharmaceutical composition comprising an antagonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with overexpression of functional CIRYP, comprising administering to a patient in need of such treatment the pharmaceutical composition.

The invention further provides a method for screening a compound for effectiveness in

altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence selected from the group consisting of SEQ ID NO:3-4, the method comprising a) exposing a sample comprising the target polynucleotide to a compound, and b) detecting altered expression of the target polynucleotide.

5

### BRIEF DESCRIPTION OF THE FIGURES AND TABLE

Figures 1A, 1B, 1C, and 1D show the amino acid sequence (SEQ ID NO:1) and nucleic acid sequence (SEQ ID NO:3) of CIRYP-1. The alignment was produced using MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco CA).

10 Figures 2A, 2B, and 2C show the amino acid sequence (SEQ ID NO:2) and nucleic acid sequence (SEQ ID NO:4) of CIRYP-2. The alignment was produced using MACDNASIS PRO software (Hitachi Software Engineering).

Figures 3A and 3B show the amino acid sequence alignment among CIRYP-2 (Incyte Clone ID 2267905; SEQ ID NO:2), CLK-1 (GI 3415017; SEQ ID NO:6), CIRYP-1 (Incyte Clone ID 1581473; SEQ ID NO:1), and Dreg-2 (GI 1561732; SEQ ID NO:5), produced using the multisequence alignment program of LASERGENE software (DNASTAR, Madison WI).

15

Table 1 shows the tools, programs, and algorithms used to analyze CIRYP, along with applicable descriptions, references, and threshold parameters.

20

### DESCRIPTION OF THE INVENTION

Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular machines, materials and methods described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

25

It must be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to "a host cell" includes a plurality of such host cells, and a reference to "an antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

30

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any machines, materials, and methods similar or equivalent to those described herein can be used to practice or test the present invention, the preferred machines, materials and methods are now



described. All publications mentioned herein are cited for the purpose of describing and disclosing the cell lines, protocols, reagents and vectors which are reported in the publications and which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

## 5 DEFINITIONS

"CIRYP" refers to the amino acid sequences of substantially purified CIRYP obtained from any species, particularly a mammalian species, including bovine, ovine, porcine, murine, equine, and human, and from any source, whether natural, synthetic, semi-synthetic, or recombinant.

The term "agonist" refers to a molecule which intensifies or mimics the biological activity of CIRYP. Agonists may include proteins, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of CIRYP either by directly interacting with CIRYP or by acting on components of the biological pathway in which CIRYP participates.

An "allelic variant" is an alternative form of the gene encoding CIRYP. Allelic variants may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. A gene may have none, one, or many allelic variants of its naturally occurring form. Common mutational changes which give rise to allelic variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

"Altered" nucleic acid sequences encoding CIRYP include those sequences with deletions, insertions, or substitutions of different nucleotides, resulting in a polypeptide the same as CIRYP or a polypeptide with at least one functional characteristic of CIRYP. Included within this definition are polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding CIRYP, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding CIRYP. The encoded protein may also be "altered," and may contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent CIRYP. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of CIRYP is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid, and positively charged amino acids may include lysine and arginine. Amino acids with uncharged polar side chains having similar hydrophilicity values may include: asparagine and glutamine; and serine and threonine. Amino acids with uncharged side chains having similar hydrophilicity values may include: leucine,

isoleucine, and valine; glycine and alanine; and phenylalanine and tyrosine.

The terms "amino acid" and "amino acid sequence" refer to an oligopeptide, peptide, polypeptide, or protein sequence, or a fragment of any of these, and to naturally occurring or synthetic molecules. Where "amino acid sequence" is recited to refer to an amino acid sequence of a naturally occurring protein molecule, "amino acid sequence" and like terms are not meant to limit the amino acid sequence to the complete native amino acid sequence associated with the recited protein molecule.

"Amplification" relates to the production of additional copies of a nucleic acid sequence. Amplification is generally carried out using polymerase chain reaction (PCR) technologies well known in the art.

The term "antagonist" refers to a molecule which inhibits or attenuates the biological activity of CIRYP. Antagonists may include proteins such as antibodies, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of CIRYP either by directly interacting with CIRYP or by acting on components of the biological pathway in which CIRYP participates.

The term "antibody" refers to intact immunoglobulin molecules as well as to fragments thereof, such as Fab, F(ab')<sub>2</sub>, and Fv fragments, which are capable of binding an epitopic determinant. Antibodies that bind CIRYP polypeptides can be prepared using intact polypeptides or using fragments containing small peptides of interest as the immunizing antigen. The polypeptide or oligopeptide used to immunize an animal (e.g., a mouse, a rat, or a rabbit) can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize the animal.

The term "antigenic determinant" refers to that region of a molecule (i.e., an epitope) that makes contact with a particular antibody. When a protein or a fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to antigenic determinants (particular regions or three-dimensional structures on the protein). An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

The term "antisense" refers to any composition containing a nucleic acid sequence which is complementary to the "sense" strand of a specific nucleic acid sequence. Antisense molecules may be produced by any method including synthesis or transcription. Once introduced into a cell, the complementary nucleotides combine with natural sequences produced by the cell to form duplexes

and to block either transcription or translation. The designation "negative" or "minus" can refer to the antisense strand, and the designation "positive" or "plus" can refer to the sense strand.

The term "biologically active" refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "immunologically active" refers to the capability of the natural, recombinant, or synthetic CIRYP, or of any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

The terms "complementary" and "complementarity" refer to the natural binding of polynucleotides by base pairing. For example, the sequence "5' A-G-T 3'" bonds to the complementary sequence "3' T-C-A 5'." Complementarity between two single-stranded molecules may be "partial," such that only some of the nucleic acids bind, or it may be "complete," such that total complementarity exists between the single stranded molecules. The degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of the hybridization between the nucleic acid strands. This is of particular importance in amplification reactions, which depend upon binding between nucleic acid strands, and in the design and use of peptide nucleic acid (PNA) molecules.

A "composition comprising a given polynucleotide sequence" and a "composition comprising a given amino acid sequence" refer broadly to any composition containing the given polynucleotide or amino acid sequence. The composition may comprise a dry formulation or an aqueous solution. Compositions comprising polynucleotide sequences encoding CIRYP or fragments of CIRYP may be employed as hybridization probes. The probes may be stored in freeze-dried form and may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts (e.g., NaCl), detergents (e.g., sodium dodecyl sulfate; SDS), and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).

"Consensus sequence" refers to a nucleic acid sequence which has been resequenced to resolve uncalled bases, extended using the XL-PCR kit (Perkin-Elmer, Norwalk CT) in the 5' and/or the 3' direction, and resequenced, or which has been assembled from the overlapping sequences of one or more Incyte Clones and, in some cases, one or more public domain ESTs, using a computer program for fragment assembly, such as the GELVIEW fragment assembly system (GCG, Madison WI). Some sequences have been both extended and assembled to produce the consensus sequence.

"Conservative amino acid substitutions" are those substitutions that, when made, least interfere with the properties of the original protein, i.e., the structure and especially the function of the protein is conserved and not significantly changed by such substitutions. The table below shows amino acids which may be substituted for an original amino acid in a protein and which are regarded as conservative amino acid substitutions.

	Original Residue	Conservative Substitution
	Ala	Gly, Ser
	Arg	His, Lys
	Asn	Asp, Gln, His
5	Asp	Asn, Glu
	Cys	Ala, Ser
	Gln	Asn, Glu, His
	Glu	Asp, Gln, His
	Gly	Ala
10	His	Asn, Arg, Gln, Glu
	Ile	Leu, Val
	Leu	Ile, Val
	Lys	Arg, Gln, Glu
	Met	Leu, Ile
15	Phe	His, Met, Leu, Trp, Tyr
	Ser	Cys, Thr
	Thr	Ser, Val
	Trp	Phe, Tyr
	Tyr	His, Phe, Trp
20	Val	Ile, Leu, Thr

Conservative amino acid substitutions generally maintain (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a beta sheet or alpha helical conformation, (b) the charge or hydrophobicity of the molecule at the site of the substitution, and/or (c) the bulk of the side chain.

A "deletion" refers to a change in the amino acid or nucleotide sequence that results in the absence of one or more amino acid residues or nucleotides.

The term "derivative" refers to the chemical modification of a polypeptide sequence, or a polynucleotide sequence. Chemical modifications of a polynucleotide sequence can include, for example, replacement of hydrogen by an alkyl, acyl, hydroxyl, or amino group. A derivative polynucleotide encodes a polypeptide which retains at least one biological or immunological function of the natural molecule. A derivative polypeptide is one modified by glycosylation, pegylation, or any similar process that retains at least one biological or immunological function of the polypeptide from which it was derived.

A "fragment" is a unique portion of CIRYP or the polynucleotide encoding CIRYP which is identical in sequence to but shorter in length than the parent sequence. A fragment may comprise up to the entire length of the defined sequence, minus one nucleotide/amino acid residue. For example, a fragment may comprise from 5 to 1000 contiguous nucleotides or amino acid residues. A fragment used as a probe, primer, antigen, therapeutic molecule, or for other purposes, may be at least 5, 10, 15, 20, 25, 30, 40, 50, 60, 75, 100, 150, 250 or at least 500 contiguous nucleotides or amino acid residues in length. Fragments may be preferentially selected from certain regions of a molecule. For example,

a polypeptide fragment may comprise a certain length of contiguous amino acids selected from the first 250 or 500 amino acids (or first 25% or 50% of a polypeptide) as shown in a certain defined sequence. Clearly these lengths are exemplary, and any length that is supported by the specification, including the Sequence Listing, tables, and figures, may be encompassed by the present embodiments.

5 A fragment of SEQ ID NO:3-4 comprises a region of unique polynucleotide sequence that specifically identifies SEQ ID NO:3-4, for example, as distinct from any other sequence in the same genome. A fragment of SEQ ID NO:3-4 is useful, for example, in hybridization and amplification technologies and in analogous methods that distinguish SEQ ID NO:3-4 from related polynucleotide sequences. The precise length of a fragment of SEQ ID NO:3-4 and the region of SEQ ID NO:3-4 to  
10 which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

A fragment of SEQ ID NO:1-2 is encoded by a fragment of SEQ ID NO:3-4. A fragment of SEQ ID NO:1-2 comprises a region of unique amino acid sequence that specifically identifies SEQ ID NO:1-2. For example, a fragment of SEQ ID NO:1-2 is useful as an immunogenic peptide for the  
15 development of antibodies that specifically recognize SEQ ID NO:1-2. The precise length of a fragment of SEQ ID NO:1-2 and the region of SEQ ID NO:1-2 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

The term "similarity" refers to a degree of complementarity. There may be partial similarity  
20 or complete similarity. The word "identity" may substitute for the word "similarity." A partially complementary sequence that at least partially inhibits an identical sequence from hybridizing to a target nucleic acid is referred to as "substantially similar." The inhibition of hybridization of the completely complementary sequence to the target sequence may be examined using a hybridization assay (Southern or northern blot, solution hybridization, and the like) under conditions of reduced  
25 stringency. A substantially similar sequence or hybridization probe will compete for and inhibit the binding of a completely similar (identical) sequence to the target sequence under conditions of reduced stringency. This is not to say that conditions of reduced stringency are such that non-specific binding is permitted, as reduced stringency conditions require that the binding of two sequences to one another be a specific (i.e., a selective) interaction. The absence of non-specific binding may be  
30 tested by the use of a second target sequence which lacks even a partial degree of complementarity (e.g., less than about 30% similarity or identity). In the absence of non-specific binding, the substantially similar sequence or probe will not hybridize to the second non-complementary target sequence.

The phrases "percent identity" and "% identity," as applied to polynucleotide sequences, refer

to the percentage of residue matches between at least two polynucleotide sequences aligned using a standardized algorithm. Such an algorithm may insert, in a standardized and reproducible way, gaps in the sequences being compared in order to optimize alignment between two sequences, and therefore achieve a more meaningful comparison of the two sequences.

5       Percent identity between polynucleotide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program. This program is part of the LASERGENE software package, a suite of molecular biological analysis programs (DNASTAR, Madison WI). CLUSTAL V is described in Higgins, D.G. and P.M. Sharp (1989) CABIOS 5:151-153 and in Higgins, D.G. et al. (1992) CABIOS  
10   8:189-191. For pairwise alignments of polynucleotide sequences, the default parameters are set as follows: Ktuple=2, gap penalty=5, window=4, and "diagonals saved"=4. The "weighted" residue weight table is selected as the default. Percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polynucleotide sequence pairs.

Alternatively, a suite of commonly used and freely available sequence comparison algorithms  
15 is provided by the National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST) (Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410), which is available from several sources, including the NCBI, Bethesda, MD, and on the Internet at <http://www.ncbi.nlm.nih.gov/BLAST/>. The BLAST software suite includes various sequence analysis programs including "blastn," that is used to align a known polynucleotide sequence with other  
20 polynucleotide sequences from a variety of databases. Also available is a tool called "BLAST 2 Sequences" that is used for direct pairwise comparison of two nucleotide sequences. "BLAST 2 Sequences" can be accessed and used interactively at <http://www.ncbi.nlm.nih.gov/gorf/bl2.html>. The "BLAST 2 Sequences" tool can be used for both blastn and blastp (discussed below). BLAST programs are commonly used with gap and other parameters set to default settings. For example, to  
25 compare two nucleotide sequences, one may use blastn with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such default parameters may be, for example:

*Matrix: BLOSUM62*

*Reward for match: 1*

*Penalty for mismatch: -2*

30   *Open Gap: 5 and Extension Gap: 2 penalties*

*Gap x drop-off: 50*

*Expect: 10*

*Word Size: 11*

*Filter: on*

Percent identity may be measured over the length of an entire defined sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined sequence, for instance, a fragment of at least 20, at least 30, at least 40, at least 50, at least 70, at least 100, or at least 200 contiguous  
 5 nucleotides. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures, or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

Nucleic acid sequences that do not show a high degree of identity may nevertheless encode similar amino acid sequences due to the degeneracy of the genetic code. It is understood that changes  
 10 in a nucleic acid sequence can be made using this degeneracy to produce multiple nucleic acid sequences that all encode substantially the same protein.

The phrases "percent identity" and "% identity," as applied to polypeptide sequences, refer to the percentage of residue matches between at least two polypeptide sequences aligned using a standardized algorithm. Methods of polypeptide sequence alignment are well-known. Some  
 15 alignment methods take into account conservative amino acid substitutions. Such conservative substitutions, explained in more detail above, generally preserve the hydrophobicity and acidity at the site of substitution, thus preserving the structure (and therefore function) of the polypeptide.

Percent identity between polypeptide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e  
 20 sequence alignment program (described and referenced above). For pairwise alignments of polypeptide sequences using CLUSTAL V, the default parameters are set as follows: Ktuple=1, gap penalty=3, window=5, and "diagonals saved"=5. The PAM250 matrix is selected as the default residue weight table. As with polynucleotide alignments, the percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polypeptide sequence pairs.

25 Alternatively the NCBI BLAST software suite may be used. For example, for a pairwise comparison of two polypeptide sequences, one may use the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) with blastp set at default parameters. Such default parameters may be, for example:

*Matrix: BLOSUM62*

*Open Gap: 11 and Extension Gap: 1 penalties*

30 *Gap x drop-off: 50*

*Expect: 10*

*Word Size: 3*

*Filter: on*

Percent identity may be measured over the length of an entire defined polypeptide sequence,

for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined polypeptide sequence, for instance, a fragment of at least 15, at least 20, at least 30, at least 40, at least 50, at least 70 or at least 150 contiguous residues. Such lengths are exemplary only, and it is understood that any fragment  
 5 length supported by the sequences shown herein, in the tables, figures or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

“Human artificial chromosomes” (HACs) are linear microchromosomes which may contain DNA sequences of about 6 kb to 10 Mb in size, and which contain all of the elements required for stable mitotic chromosome segregation and maintenance.

10 The term “humanized antibody” refers to antibody molecules in which the amino acid sequence in the non-antigen binding regions has been altered so that the antibody more closely resembles a human antibody, and still retains its original binding ability.

“Hybridization” refers to the process by which a polynucleotide strand anneals with a complementary strand through base pairing under defined hybridization conditions. Specific  
 15 hybridization is an indication that two nucleic acid sequences share a high degree of identity. Specific hybridization complexes form under permissive annealing conditions and remain hybridized after the “washing” step(s). The washing step(s) is particularly important in determining the stringency of the hybridization process, with more stringent conditions allowing less non-specific binding, i.e., binding between pairs of nucleic acid strands that are not perfectly matched. Permissive conditions for  
 20 annealing of nucleic acid sequences are routinely determinable by one of ordinary skill in the art and may be consistent among hybridization experiments, whereas wash conditions may be varied among experiments to achieve the desired stringency, and therefore hybridization specificity. Permissive annealing conditions occur, for example, at 68°C in the presence of about 6 x SSC, about 1% (w/v) SDS, and about 100 µg/ml denatured salmon sperm DNA.

25 Generally, stringency of hybridization is expressed, in part, with reference to the temperature under which the wash step is carried out. Generally, such wash temperatures are selected to be about 5°C to 20°C lower than the thermal melting point ( $T_m$ ) for the specific sequence at a defined ionic strength and pH. The  $T_m$  is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. An equation for calculating  $T_m$  and  
 30 conditions for nucleic acid hybridization are well known and can be found in Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, 2<sup>nd</sup> ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; specifically see volume 2, chapter 9.

High stringency conditions for hybridization between polynucleotides of the present invention include wash conditions of 68°C in the presence of about 0.2 x SSC and about 0.1% SDS, for 1 hour.



Alternatively, temperatures of about 65°C, 60°C, 55°C, or 42°C may be used. SSC concentration may be varied from about 0.1 to 2 x SSC, with SDS being present at about 0.1%. Typically, blocking reagents are used to block non-specific hybridization. Such blocking reagents include, for instance, denatured salmon sperm DNA at about 100-200 µg/ml. Organic solvent, such as formamide at a concentration of about 35-50% v/v, may also be used under particular circumstances, such as for RNA:DNA hybridizations. Useful variations on these wash conditions will be readily apparent to those of ordinary skill in the art. Hybridization, particularly under high stringency conditions, may be suggestive of evolutionary similarity between the nucleotides. Such similarity is strongly indicative of a similar role for the nucleotides and their encoded polypeptides.

The term "hybridization complex" refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary bases. A hybridization complex may be formed in solution (e.g., C<sub>0</sub>t or R<sub>0</sub>t analysis) or formed between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate substrate to which cells or their nucleic acids have been fixed).

The words "insertion" and "addition" refer to changes in an amino acid or nucleotide sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively.

"Immune response" can refer to conditions associated with inflammation, trauma, immune disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression of various factors, e.g., cytokines, chemokines, and other signaling molecules, which may affect cellular and systemic defense systems.

The term "microarray" refers to an arrangement of distinct polynucleotides on a substrate.

The terms "element" and "array element" in a microarray context, refer to hybridizable polynucleotides arranged on the surface of a substrate.

The term "modulate" refers to a change in the activity of CIRYP. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of CIRYP.

The phrases "nucleic acid" and "nucleic acid sequence" refer to a nucleotide, oligonucleotide, polynucleotide, or any fragment thereof. These phrases also refer to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material.

"Operably linked" refers to the situation in which a first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding

sequence. Generally, operably linked DNA sequences may be in close proximity or contiguous and, where necessary to join two protein coding regions, in the same reading frame.

“Peptide nucleic acid” (PNA) refers to an antisense molecule or anti-gene agent which comprises an oligonucleotide of at least about 5 nucleotides in length linked to a peptide backbone of amino acid residues ending in lysine. The terminal lysine confers solubility to the composition. PNAs preferentially bind complementary single stranded DNA or RNA and stop transcript elongation, and may be pegylated to extend their lifespan in the cell.

“Probe” refers to nucleic acid sequences encoding CIRYP, their complements, or fragments thereof, which are used to detect identical, allelic or related nucleic acid sequences. Probes are isolated oligonucleotides or polynucleotides attached to a detectable label or reporter molecule. Typical labels include radioactive isotopes, ligands, chemiluminescent agents, and enzymes.

“Primers” are short nucleic acids, usually DNA oligonucleotides, which may be annealed to a target polynucleotide by complementary base-pairing. The primer may then be extended along the target DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification (and identification) of a nucleic acid sequence, e.g., by the polymerase chain reaction (PCR).

Probes and primers as used in the present invention typically comprise at least 15 contiguous nucleotides of a known sequence. In order to enhance specificity, longer probes and primers may also be employed, such as probes and primers that comprise at least 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, or at least 150 consecutive nucleotides of the disclosed nucleic acid sequences. Probes and primers may be considerably longer than these examples, and it is understood that any length supported by the specification, including the tables, figures, and Sequence Listing, may be used.

Methods for preparing and using probes and primers are described in the references, for example Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, 2<sup>nd</sup> ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; Ausubel et al., 1987, Current Protocols in Molecular Biology, Greene Publ. Assoc. & Wiley-Intersciences, New York NY; Innis et al., 1990, PCR Protocols, A Guide to Methods and Applications, Academic Press, San Diego CA. PCR primer pairs can be derived from a known sequence, for example, by using computer programs intended for that purpose such as Primer (Version 0.5, 1991, Whitehead Institute for Biomedical Research, Cambridge MA).

Oligonucleotides for use as primers are selected using software known in the art for such purpose. For example, OLIGO 4.06 software is useful for the selection of PCR primer pairs of up to 100 nucleotides each, and for the analysis of oligonucleotides and larger polynucleotides of up to 5,000 nucleotides from an input polynucleotide sequence of up to 32 kilobases. Similar primer selection programs have incorporated additional features for expanded capabilities. For example, the PrimOU primer selection program (available to the public from the Genome Center at University of

Texas South West Medical Center, Dallas TX) is capable of choosing specific primers from megabase sequences and is thus useful for designing primers on a genome-wide scope. The Primer3 primer selection program (available to the public from the Whitehead Institute/MIT Center for Genome Research, Cambridge MA) allows the user to input a "mispriming library," in which sequences to avoid as primer binding sites are user-specified. Primer3 is useful, in particular, for the selection of oligonucleotides for microarrays. (The source code for the latter two primer selection programs may also be obtained from their respective sources and modified to meet the user's specific needs.) The PrimeGen program (available to the public from the UK Human Genome Mapping Project Resource Centre, Cambridge UK) designs primers based on multiple sequence alignments, thereby allowing selection of primers that hybridize to either the most conserved or least conserved regions of aligned nucleic acid sequences. Hence, this program is useful for identification of both unique and conserved oligonucleotides and polynucleotide fragments. The oligonucleotides and polynucleotide fragments identified by any of the above selection methods are useful in hybridization technologies, for example, as PCR or sequencing primers, microarray elements, or specific probes to identify fully or partially complementary polynucleotides in a sample of nucleic acids. Methods of oligonucleotide selection are not limited to those described above.

A "recombinant nucleic acid" is a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two or more otherwise separated segments of sequence. This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques such as those described in Sambrook, *supra*. The term recombinant includes nucleic acids that have been altered solely by addition, substitution, or deletion of a portion of the nucleic acid. Frequently, a recombinant nucleic acid may include a nucleic acid sequence operably linked to a promoter sequence. Such a recombinant nucleic acid may be part of a vector that is used, for example, to transform a cell.

Alternatively, such recombinant nucleic acids may be part of a viral vector, e.g., based on a vaccinia virus, that could be used to vaccinate a mammal wherein the recombinant nucleic acid is expressed, inducing a protective immunological response in the mammal.

The term "sample" is used in its broadest sense. A sample suspected of containing nucleic acids encoding CIRYP, or fragments thereof, or CIRYP itself, may comprise a bodily fluid; an extract from a cell, chromosome, organelle, or membrane isolated from a cell; a cell; genomic DNA, RNA, or cDNA, in solution or bound to a substrate; a tissue; a tissue print; etc.

The terms "specific binding" and "specifically binding" refer to that interaction between a protein or peptide and an agonist, an antibody, an antagonist, a small molecule, or any natural or

synthetic binding composition. The interaction is dependent upon the presence of a particular structure of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope "A," the presence of a polypeptide containing the epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds to the antibody.

The term "substantially purified" refers to nucleic acid or amino acid sequences that are removed from their natural environment and are isolated or separated, and are at least 60% free, preferably at least 75% free, and most preferably at least 90% free from other components with which they are naturally associated.

A "substitution" refers to the replacement of one or more amino acids or nucleotides by different amino acids or nucleotides, respectively.

"Substrate" refers to any suitable rigid or semi-rigid support including membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers, microparticles and capillaries. The substrate can have a variety of surface forms, such as wells, trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound.

"Transformation" describes a process by which exogenous DNA enters and changes a recipient cell. Transformation may occur under natural or artificial conditions according to various methods well known in the art, and may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method for transformation is selected based on the type of host cell being transformed and may include, but is not limited to, viral infection, electroporation, heat shock, lipofection, and particle bombardment. The term "transformed" cells includes stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome, as well as transiently transformed cells which express the inserted DNA or RNA for limited periods of time.

A "variant" of a particular nucleic acid sequence is defined as a nucleic acid sequence having at least 40% sequence identity to the particular nucleic acid sequence over a certain length of one of the nucleic acid sequences using blastn with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of nucleic acids may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95% or at least 98% or greater sequence identity over a certain defined length. A variant may be described as, for example, an "allelic" (as defined above), "splice," "species," or "polymorphic" variant. A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternate splicing of exons during mRNA processing. The corresponding polypeptide may possess additional functional domains or lack domains that are present in the

reference molecule. Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides generally will have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass "single nucleotide polymorphisms" (SNPs) in which the polynucleotide sequence varies by one nucleotide base. The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.

A "variant" of a particular polypeptide sequence is defined as a polypeptide sequence having at least 40% sequence identity to the particular polypeptide sequence over a certain length of one of the polypeptide sequences using blastp with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of polypeptides may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 98% or greater sequence identity over a certain defined length of one of the polypeptides.

#### THE INVENTION

The invention is based on the discovery of new human proteins associated with circadian rhythms (CIRYP), the polynucleotides encoding CIRYP, and the use of these compositions for the diagnosis, treatment, or prevention of reproductive disorders, gastrointestinal disorders, neuronal disorders, and developmental disorders.

Nucleic acids encoding the CIRYP-1 of the present invention were identified in Incyte Clone 1581473H1 from the duodenal cDNA library (DUODNOT01) using a computer search for nucleotide and/or amino acid sequence alignments. A consensus sequence, SEQ ID NO:3, was assembled from the following overlapping and/or extended nucleic acid sequences: Incyte Clones 1581473H1 (DUODNOT01), 2604921H1 (LUNGTUT07), 816118R1 (OVRTUT01), 3253364H1 (OVRTUN01), 879455T1 (THYRNOT02), and 1312037F1 (COLNFET02).

In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:1, as shown in Figures 1A, 1B, 1C, and 1D. CIRYP-1 is 251 amino acids in length and has three potential casein kinase II phosphorylation sites at residues S43, T120 and S135; and two potential protein kinase C phosphorylation sites at T70 and T120. As shown in Figures 3A and 3B, CIRYP-1 has chemical and structural similarity with CIRYP-2 (SEQ ID NO:2), Dreg-2 (GI 1561732; SEQ ID NO:5), and CLK-1 (GI 3415017; SEQ ID NO:6). In particular, CIRYP-1 and Dreg-2 share 32% identity. CIRYP-1 and Dreg-2 are very similar in length, with 252 and 255 amino acids, respectively. CIRYP-1, CIRYP-2, Dreg-2, and CLK-1 share 11 conserved amino acid residues. These residues in CIRYP-1 are M1, R22, W111, F137, R140, L150, F156, K167, A176, Y198, and L210. In addition, CIRYP-1 shares conserved hydrophobic residues with CIRYP-2, Dreg-2, and

CLK-1. Those residues in CIRYP-1 are F83, G87, V94, L101, I145, M182, and F209. A fragment of SEQ ID NO:3 from about nucleotide 417 to about nucleotide 476 is useful, for example, in hybridization or amplification technologies to identify SEQ ID NO:3 and to distinguish between SEQ ID NO:3 and a related sequence. The encoded polypeptide is useful, for example, as an immunogenic peptide. Northern analysis shows the expression of this sequence in various libraries, at least 58% of which are associated with cancer and at least 18% of which are associated with inflammation and the immune response. Of particular note is the expression of CIRYP-1 in gastrointestinal tissue.

Nucleic acids encoding the CIRYP-2 of the present invention were identified in Incyte Clone 2267905H1 from the uterine cDNA library (UTRSNOT02) using a computer search for nucleotide and/or amino acid sequence alignments. A consensus sequence, SEQ ID NO:4, was assembled from the following overlapping and/or extended nucleic acid sequences: Incyte Clones 2267905H1 (UTRSNOT02), 2267905R6 (UTRSNOT02), 1550606H1 (PROSNOT06), 1683318F6 (PROSNOT15), 4594189H1 (PROSTUT18), and 2733567H1 (OVARTUT04), and the shotgun sequence SAE01465R1.

In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:2, as shown in Figures 2A, 2B, and 2C. CIRYP-2 is 217 amino acids in length and has one potential N-glycosylation site at residue N43; one potential cAMP- and cGMP-dependent protein kinase phosphorylation site at S31; one potential casein kinase II phosphorylation site at T155; and two potential protein kinase C phosphorylation sites at S31 and S214. As shown in Figures 3A and 3B, CIRYP-2 has chemical and structural similarity with CLK-1 (GI 3415017; SEQ ID NO:6), CIRYP-1 (SEQ ID NO:1), and Dreg-2 (GI 1561732; SEQ ID NO:5). In particular, CIRYP-2 and CLK-1 share 85% identity. CIRYP-2 and CLK-1 are both 217 amino acids long. As noted above, CIRYP-1, CIRYP-2, Dreg-2, and CLK-1 share 11 conserved amino acid residues. These residues in CIRYP-2 are M1, R16, W87, F104, R107, L114, F120, K131, A140, Y164, and L168. As also noted above, CIRYP-2 shares conserved hydrophobic residues with CLK-1, CIRYP-1, and Dreg-2. Those residues in CIRYP-2 are Y67, M71, V79, M86, L111, and Y149. Note the presence of a TRC domain in both CIRYP-2 and CLK-1 which spans from about residue A58 to about residue L129, and repeats itself from about residue A140 to about residue L217. A fragment of SEQ ID NO:4 from about nucleotide 77 to about nucleotide 148 is useful, for example, in hybridization or amplification technologies to identify SEQ ID NO:4 and to distinguish between SEQ ID NO:4 and a related sequence. The encoded polypeptide is useful, for example, as an immunogenic peptide. Northern analysis shows the expression of this sequence in various libraries, at least 67% of which are associated with cancer and at least 19% of which are associated with inflammation and the immune response. Of particular note is the high expression of CIRYP-2 in reproductive tissue (48%).

The invention also encompasses CIRYP variants. A preferred CIRYP variant is one which has at least about 80%, or alternatively at least about 90%, or even at least about 95% amino acid sequence identity to the CIRYP amino acid sequence, and which contains at least one functional or structural characteristic of CIRYP.

5       The invention also encompasses polynucleotides which encode CIRYP. In a particular embodiment, the invention encompasses a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:3-4, which encodes CIRYP.

10       The invention also encompasses a variant of a polynucleotide sequence encoding CIRYP. In particular, such a variant polynucleotide sequence will have at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to the polynucleotide sequence encoding CIRYP. A particular aspect of the invention encompasses a variant of a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:3-4 which has at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to a nucleic acid sequence selected from the group consisting of  
15       SEQ ID NO:3-4. Any one of the polynucleotide variants described above can encode an amino acid sequence which contains at least one functional or structural characteristic of CIRYP.

It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of polynucleotide sequences encoding CIRYP, some bearing minimal similarity to the polynucleotide sequences of any known and naturally occurring gene, may be  
20       produced. Thus, the invention contemplates each and every possible variation of polynucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the polynucleotide sequence of naturally occurring CIRYP, and all such variations are to be considered as being specifically disclosed.

25       Although nucleotide sequences which encode CIRYP and its variants are generally capable of hybridizing to the nucleotide sequence of the naturally occurring CIRYP under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding CIRYP or its derivatives possessing a substantially different codon usage, e.g., inclusion of non-naturally occurring codons. Codons may be selected to increase the rate at which expression of the peptide  
30       occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding CIRYP and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

The invention also encompasses production of DNA sequences which encode CIRYP and CIRYP derivatives, or fragments thereof, entirely by synthetic chemistry. After production, the synthetic sequence may be inserted into any of the many available expression vectors and cell systems using reagents well known in the art. Moreover, synthetic chemistry may be used to introduce  
5 mutations into a sequence encoding CIRYP or any fragment thereof.

Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed polynucleotide sequences, and, in particular, to those shown in SEQ ID NO:3-4 and fragments thereof under various conditions of stringency. (See, e.g., Wahl, G.M. and S.L. Berger (1987) *Methods Enzymol.* 152:399-407; Kimmel, A.R. (1987) *Methods Enzymol.*  
10 152:507-511.) Hybridization conditions, including annealing and wash conditions, are described in "Definitions."

Methods for DNA sequencing are well known in the art and may be used to practice any of the embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of DNA polymerase I, SEQUENASE (US Biochemical, Cleveland OH), Taq polymerase (Perkin-  
15 Elmer), thermostable T7 polymerase (Amersham Pharmacia Biotech, Piscataway NJ), or combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE amplification system (Life Technologies, Gaithersburg MD). Preferably, sequence preparation is automated with machines such as the MICROLAB 2200 liquid transfer system (Hamilton, Reno NV), PTC200 thermal cycler (MJ Research, Watertown MA) and ABI CATALYST 800 thermal cycler  
20 (Perkin-Elmer). Sequencing is then carried out using either the ABI 373 or 377 DNA sequencing system (Perkin-Elmer), the MEGABACE 1000 DNA sequencing system (Molecular Dynamics, Sunnyvale CA), or other systems known in the art. The resulting sequences are analyzed using a variety of algorithms which are well known in the art. (See, e.g., Ausubel, F.M. (1997) Short Protocols in Molecular Biology, John Wiley & Sons, New York NY, unit 7.7; Meyers, R.A. (1995)  
25 Molecular Biology and Biotechnology, Wiley VCH, New York NY, pp. 856-853.)

The nucleic acid sequences encoding CIRYP may be extended utilizing a partial nucleotide sequence and employing various PCR-based methods known in the art to detect upstream sequences, such as promoters and regulatory elements. For example, one method which may be employed, restriction-site PCR, uses universal and nested primers to amplify unknown sequence from genomic  
30 DNA within a cloning vector. (See, e.g., Sarkar, G. (1993) *PCR Methods Applic.* 2:318-322.) Another method, inverse PCR, uses primers that extend in divergent directions to amplify unknown sequence from a circularized template. The template is derived from restriction fragments comprising a known genomic locus and surrounding sequences. (See, e.g., Triglia, T. et al. (1988) *Nucleic Acids Res.* 16:8186.) A third method, capture PCR, involves PCR amplification of DNA fragments adjacent



to known sequences in human and yeast artificial chromosome DNA. (See, e.g., Lagerstrom, M. et al. (1991) PCR Methods Applic. 1:111-119.) In this method, multiple restriction enzyme digestions and ligations may be used to insert an engineered double-stranded sequence into a region of unknown sequence before performing PCR. Other methods which may be used to retrieve unknown sequences are known in the art. (See, e.g., Parker, J.D. et al. (1991) Nucleic Acids Res. 19:3055-3060). Additionally, one may use PCR, nested primers, and PROMOTERFINDER libraries (Clontech, Palo Alto CA) to walk genomic DNA. This procedure avoids the need to screen libraries and is useful in finding intron/exon junctions. For all PCR-based methods, primers may be designed using commercially available software, such as OLIGO 4.06 Primer Analysis software (National Biosciences, Plymouth MN) or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the template at temperatures of about 68°C to 72°C.

When screening for full-length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. In addition, random-primed libraries, which often include sequences containing the 5' regions of genes, are preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5' non-transcribed regulatory regions.

Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different nucleotide-specific, laser-stimulated fluorescent dyes, and a charge coupled device camera for detection of the emitted wavelengths. Output/light intensity may be converted to electrical signal using appropriate software (e.g., GENOTYPER and SEQUENCE NAVIGATOR, Perkin-Elmer), and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for sequencing small DNA fragments which may be present in limited amounts in a particular sample.

In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode CIRYP may be cloned in recombinant DNA molecules that direct expression of CIRYP, or fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and used to express CIRYP.

The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter CIRYP-encoding sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA

shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, oligonucleotide-mediated site-directed mutagenesis may be used to introduce mutations that create new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth.

5           The nucleotides of the present invention may be subjected to DNA shuffling techniques such as MOLECULARBREEDING (Maxygen Inc., Santa Clara CA; described in U.S. Patent Number 5,837,458; Chang, C.-C. et al. (1999) Nat. Biotechnol. 17:793-797; Christians, F.C. et al. (1999) Nat. Biotechnol. 17:259-264; and Cramer, A. et al. (1996) Nat. Biotechnol. 14:315-319) to alter or improve the biological properties of CIRYP, such as its biological or enzymatic activity or its ability to bind to other molecules or compounds. DNA shuffling is a process by which a library of gene variants is produced using PCR-mediated recombination of gene fragments. The library is then subjected to selection or screening procedures that identify those gene variants with the desired properties. These preferred variants may then be pooled and further subjected to recursive rounds of DNA shuffling and selection/screening. Thus, genetic diversity is created through "artificial" breeding and rapid molecular evolution. For example, fragments of a single gene containing random point mutations may be recombined, screened, and then reshuffled until the desired properties are optimized. Alternatively, fragments of a given gene may be recombined with fragments of homologous genes in the same gene family, either from the same or different species, thereby maximizing the genetic diversity of multiple naturally occurring genes in a directed and controllable manner.

          In another embodiment, sequences encoding CIRYP may be synthesized, in whole or in part, using chemical methods well known in the art. (See, e.g., Caruthers, M.H. et al. (1980) Nucleic Acids Symp. Ser. 7:215-223; and Horn, T. et al. (1980) Nucleic Acids Symp. Ser. 7:225-232.) Alternatively, CIRYP itself or a fragment thereof may be synthesized using chemical methods. For example, peptide synthesis can be performed using various solid-phase techniques. (See, e.g., Roberge, J.Y. et al. (1995) Science 269:202-204.) Automated synthesis may be achieved using the ABI 431A peptide synthesizer (Perkin-Elmer). Additionally, the amino acid sequence of CIRYP, or any part thereof, may be altered during direct synthesis and/or combined with sequences from other proteins, or any part thereof, to produce a variant polypeptide.

30           The peptide may be substantially purified by preparative high performance liquid chromatography. (See, e.g., Chiez, R.M. and F.Z. Regnier (1990) Methods Enzymol. 182:392-421.) The composition of the synthetic peptides may be confirmed by amino acid analysis or by sequencing. (See, e.g., Creighton, T. (1984) Proteins, Structures and Molecular Properties, WH Freeman, New York NY.)

In order to express a biologically active CIRYP, the nucleotide sequences encoding CIRYP or derivatives thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. These elements include regulatory sequences, such as enhancers, constitutive and  
5 inducible promoters, and 5' and 3' untranslated regions in the vector and in polynucleotide sequences encoding CIRYP. Such elements may vary in their strength and specificity. Specific initiation signals may also be used to achieve more efficient translation of sequences encoding CIRYP. Such signals include the ATG initiation codon and adjacent sequences, e.g. the Kozak sequence. In cases where sequences encoding CIRYP and its initiation codon and upstream regulatory sequences are inserted  
10 into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals including an in-frame ATG initiation codon should be provided by the vector. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of  
15 enhancers appropriate for the particular host cell system used. (See, e.g., Scharf, D. et al. (1994) Results Probl. Cell Differ. 20:125-162.)

Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding CIRYP and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques,  
20 and in vivo genetic recombination. (See, e.g., Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview NY, ch. 4, 8, and 16-17; Ausubel, F.M. et al. (1995) Current Protocols in Molecular Biology, John Wiley & Sons, New York NY, ch. 9, 13, and 16.)

A variety of expression vector/host systems may be utilized to contain and express sequences  
25 encoding CIRYP. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); plant cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or  
30 animal cell systems. The invention is not limited by the host cell employed.

In bacterial systems, a number of cloning and expression vectors may be selected depending upon the use intended for polynucleotide sequences encoding CIRYP. For example, routine cloning, subcloning, and propagation of polynucleotide sequences encoding CIRYP can be achieved using a multifunctional E. coli vector such as PBLUESCRIPT (Stratagene, La Jolla CA) or PSPORT1

plasmid (Life Technologies). Ligation of sequences encoding CIRYP into the vector's multiple cloning site disrupts the *lacZ* gene, allowing a colorimetric screening procedure for identification of transformed bacteria containing recombinant molecules. In addition, these vectors may be useful for in vitro transcription, dideoxy sequencing, single strand rescue with helper phage, and creation of  
5 nested deletions in the cloned sequence. (See, e.g., Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509.) When large quantities of CIRYP are needed, e.g. for the production of antibodies, vectors which direct high level expression of CIRYP may be used. For example, vectors containing the strong, inducible T5 or T7 bacteriophage promoter may be used.

Yeast expression systems may be used for production of CIRYP. A number of vectors  
10 containing constitutive or inducible promoters, such as alpha factor, alcohol oxidase, and PGH promoters, may be used in the yeast *Saccharomyces cerevisiae* or *Pichia pastoris*. In addition, such vectors direct either the secretion or intracellular retention of expressed proteins and enable integration of foreign sequences into the host genome for stable propagation. (See, e.g., Ausubel, 1995, supra; Bitter, G.A. et al. (1987) Methods Enzymol. 153:516-544; and Scorer, C.A. et al. (1994)  
15 Bio/Technology 12:181-184.)

Plant systems may also be used for expression of CIRYP. Transcription of sequences encoding CIRYP may be driven viral promoters, e.g., the 35S and 19S promoters of CaMV used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) EMBO J. 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock  
20 promoters may be used. (See, e.g., Coruzzi, G. et al. (1984) EMBO J. 3:1671-1680; Broglie, R. et al. (1984) Science 224:838-843; and Winter, J. et al. (1991) Results Probl. Cell Differ. 17:85-105.) These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. (See, e.g., The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York NY, pp. 191-196.)

25 In mammalian cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding CIRYP may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain infective virus which expresses CIRYP in host cells. (See, e.g., Logan, J. and T. Shenk (1984) Proc.  
30 Natl. Acad. Sci. USA 81:3655-3659.) In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells. SV40 or EBV-based vectors may also be used for high-level protein expression.

Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained in and expressed from a plasmid. HACs of about 6 kb to 10 Mb are

constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes. (See, e.g., Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355.)

For long term production of recombinant proteins in mammalian systems, stable expression of CIRYP in cell lines is preferred. For example, sequences encoding CIRYP can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for about 1 to 2 days in enriched media before being switched to selective media. The purpose of the selectable marker is to confer resistance to a selective agent, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be propagated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase and adenine phosphoribosyltransferase genes, for use in *tk* and *apr* cells, respectively. (See, e.g., Wigler, M. et al. (1977) Cell 11:223-232; Lowy, I. et al. (1980) Cell 22:817-823.) Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, *dhfr* confers resistance to methotrexate; *neo* confers resistance to the aminoglycosides neomycin and G-418; and *als* and *pat* confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. (See, e.g., Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. USA 77:3567-3570; Colbere-Garapin, F. et al. (1981) J. Mol. Biol. 150:1-14.) Additional selectable genes have been described, e.g., *trpB* and *hisD*, which alter cellular requirements for metabolites. (See, e.g., Hartman, S.C. and R.C. Mulligan (1988) Proc. Natl. Acad. Sci. USA 85:8047-8051.) Visible markers, e.g., anthocyanins, green fluorescent proteins (GFP; Clontech),  $\beta$  glucuronidase and its substrate  $\beta$ -glucuronide, or luciferase and its substrate luciferin may be used. These markers can be used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system. (See, e.g., Rhodes, C.A. (1995) Methods Mol. Biol. 55:121-131.)

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, the presence and expression of the gene may need to be confirmed. For example, if the sequence encoding CIRYP is inserted within a marker gene sequence, transformed cells containing sequences encoding CIRYP can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding CIRYP under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

In general, host cells that contain the nucleic acid sequence encoding CIRYP and that express CIRYP may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations, PCR amplification, and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein sequences.

Immunological methods for detecting and measuring the expression of CIRYP using either specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on CIRYP is preferred, but a competitive binding assay may be employed. These and other assays are well known in the art. (See, e.g., Hampton, R. et al. (1990) Serological Methods, a Laboratory Manual, APS Press, St. Paul MN, Sect. IV; Coligan, J.E. et al. (1997) Current Protocols in Immunology, Greene Pub. Associates and Wiley-Interscience, New York NY; and Pound, J.D. (1998) Immunochemical Protocols, Humana Press, Totowa NJ.)

A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding CIRYP include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, the sequences encoding CIRYP, or any fragments thereof, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits, such as those provided by Amersham Pharmacia Biotech, Promega (Madison WI), and US Biochemical. Suitable reporter molecules or labels which may be used for ease of detection include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

Host cells transformed with nucleotide sequences encoding CIRYP may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a transformed cell may be secreted or retained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode CIRYP may be designed to contain signal sequences which direct secretion of CIRYP through a prokaryotic or eukaryotic cell membrane.

In addition, a host cell strain may be chosen for its ability to modulate expression of the

inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" or "pro" form of the protein may also be used to specify protein targeting, folding, and/or activity.

- 5 Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and WI38) are available from the American Type Culture Collection (ATCC, Manassas VA) and may be chosen to ensure the correct modification and processing of the foreign protein.

- 10 In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding CIRYP may be ligated to a heterologous sequence resulting in translation of a fusion protein in any of the aforementioned host systems. For example, a chimeric CIRYP protein containing a heterologous moiety that can be recognized by a commercially available antibody may facilitate the screening of peptide libraries for inhibitors of CIRYP activity. Heterologous protein and peptide moieties may also facilitate purification of fusion proteins using commercially available
- 15 affinity matrices. Such moieties include, but are not limited to, glutathione S-transferase (GST), maltose binding protein (MBP), thioredoxin (Trx), calmodulin binding peptide (CBP), 6-His, FLAG, *c-myc*, and hemagglutinin (HA). GST, MBP, Trx, CBP, and 6-His enable purification of their cognate fusion proteins on immobilized glutathione, maltose, phenylarsine oxide, calmodulin, and metal-chelate resins, respectively. FLAG, *c-myc*, and hemagglutinin (HA) enable immunoaffinity
- 20 purification of fusion proteins using commercially available monoclonal and polyclonal antibodies that specifically recognize these epitope tags. A fusion protein may also be engineered to contain a proteolytic cleavage site located between the CIRYP encoding sequence and the heterologous protein sequence, so that CIRYP may be cleaved away from the heterologous moiety following purification. Methods for fusion protein expression and purification are discussed in Ausubel (1995, supra, ch. 10).
- 25 A variety of commercially available kits may also be used to facilitate expression and purification of fusion proteins.

- In a further embodiment of the invention, synthesis of radiolabeled CIRYP may be achieved in vitro using the TNT rabbit reticulocyte lysate or wheat germ extract system (Promega). These systems couple transcription and translation of protein-coding sequences operably associated with the
- 30 T7, T3, or SP6 promoters. Translation takes place in the presence of a radiolabeled amino acid precursor, for example, <sup>35</sup>S-methionine.

Fragments of CIRYP may be produced not only by recombinant means, but also by direct peptide synthesis using solid-phase techniques. (See, e.g., Creighton, supra, pp. 55-60.) Protein synthesis may be performed by manual techniques or by automation. Automated synthesis may be

achieved, for example, using the ABI 431A peptide synthesizer (Perkin-Elmer). Various fragments of CIRYP may be synthesized separately and then combined to produce the full length molecule.

### THERAPEUTICS

Chemical and structural similarity, e.g., in the context of sequences and motifs, exists between  
5 regions of CIRYP and proteins that play a role in biological timing, such as Dreg-2 (GI 1561732)  
from D. melanogaster, and mouse CLK-1 (GI 3415017). In addition, the expression of CIRYP is  
closely associated with gastrointestinal, reproductive, and nervous tissues. Therefore, CIRYP appears  
to play a role in reproductive disorders, gastrointestinal disorders, neuronal disorders, and  
developmental disorders. In the treatment of disorders associated with increased CIRYP expression  
10 or activity, it is desirable to decrease the expression or activity of CIRYP. In the treatment of  
disorders associated with decreased CIRYP expression or activity, it is desirable to increase the  
expression or activity of CIRYP.

Therefore, in one embodiment, CIRYP or a fragment or derivative thereof may be  
administered to a subject to treat or prevent a disorder associated with decreased expression or  
15 activity of CIRYP. Examples of such disorders include, but are not limited to, a reproductive  
disorder, such as disorders of prolactin production, infertility (including tubal disease, ovulatory  
defects, and endometriosis), disruptions of the estrous cycle, disruptions of the menstrual cycle,  
polycystic ovary syndrome, ovarian hyperstimulation syndrome, endometrial and ovarian tumors,  
uterine fibroids, autoimmune disorders, ectopic pregnancies, teratogenesis, cancer of the breast,  
20 fibrocystic breast disease, galactorrhea, disruptions of spermatogenesis, abnormal sperm physiology,  
cancer of the testis, cancer of the prostate, benign prostatic hyperplasia, prostatitis, Peyronie's disease,  
impotence, carcinoma of the male breast, and gynecomastia; a gastrointestinal disorder, such as  
dysphagia, peptic esophagitis, esophageal spasm, esophageal stricture, esophageal carcinoma,  
dyspepsia, indigestion, gastritis, gastric carcinoma, anorexia, nausea, emesis, gastroparesis, antral or  
25 pyloric edema, abdominal angina, pyrosis, gastroenteritis, intestinal obstruction, infections of the  
intestinal tract, peptic ulcer, cholelithiasis, cholecystitis, cholestasis, pancreatitis, pancreatic  
carcinoma, biliary tract disease, hepatitis, hyperbilirubinemia, cirrhosis, passive congestion of the  
liver, hepatoma, infectious colitis, ulcerative colitis, ulcerative proctitis, Crohn's disease, Whipple's  
disease, Mallory-Weiss syndrome, colonic carcinoma, colonic obstruction, irritable bowel syndrome,  
30 short bowel syndrome, diarrhea, constipation, gastrointestinal hemorrhage, and acquired  
immunodeficiency syndrome (AIDS) enteropathy; a neuronal disorder, such as akathisia, Alzheimer's  
disease, amnesia, amyotrophic lateral sclerosis, bipolar disorder, catatonia, cerebral neoplasms,  
dementia, depression, diabetic neuropathy, Down's syndrome, tardive dyskinesia, dystonias, epilepsy,  
Huntington's disease, peripheral neuropathy, multiple sclerosis, neurofibromatosis, Parkinson's



disease, paranoid psychoses, postherpetic neuralgia, schizophrenia, seasonal affective disorder (SAD), and Tourette's disorder; and a developmental disorder, such as renal tubular acidosis, anemia, Cushing's syndrome, achondroplastic dwarfism, Duchenne and Becker muscular dystrophy, epilepsy, gonadal dysgenesis, WAGR syndrome (Wilms' tumor, aniridia, genitourinary abnormalities, and mental retardation), Smith-Magenis syndrome, myelodysplastic syndrome, hereditary mucoepithelial dysplasia, hereditary keratodermas, hereditary neuropathies such as Charcot-Marie-Tooth disease and neurofibromatosis, hypothyroidism, hydrocephalus, seizure disorders such as Sydenham's chorea and cerebral palsy, spina bifida, anencephaly, craniorachischisis, congenital glaucoma, cataract, and sensorineural hearing loss.

10 In another embodiment, a vector capable of expressing CIRYP or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of CIRYP including, but not limited to, those described above.

In a further embodiment, a pharmaceutical composition comprising a substantially purified CIRYP in conjunction with a suitable pharmaceutical carrier may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of CIRYP including, but not limited to, those provided above.

In still another embodiment, an agonist which modulates the activity of CIRYP may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of CIRYP including, but not limited to, those listed above.

20 In a further embodiment, an antagonist of CIRYP may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of CIRYP. Examples of such disorders include, but are not limited to, those reproductive disorders, gastrointestinal disorders, neuronal disorders, and developmental disorders described above. In one aspect, an antibody which specifically binds CIRYP may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissues which express CIRYP.

25 In an additional embodiment, a vector expressing the complement of the polynucleotide encoding CIRYP may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of CIRYP including, but not limited to, those described above.

In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary sequences, or vectors of the invention may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic

efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

An antagonist of CIRYP may be produced using methods which are generally known in the art. In particular, purified CIRYP may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind CIRYP. Antibodies to CIRYP may also be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies (i.e., those which inhibit dimer formation) are generally preferred for therapeutic use.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others may be immunized by injection with CIRYP or with any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, KLH, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are especially preferable.

It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to CIRYP have an amino acid sequence consisting of at least about 5 amino acids, and generally will consist of at least about 10 amino acids. It is also preferable that these oligopeptides, peptides, or fragments are identical to a portion of the amino acid sequence of the natural protein and contain the entire amino acid sequence of a small, naturally occurring molecule. Short stretches of CIRYP amino acids may be fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be produced.

Monoclonal antibodies to CIRYP may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique. (See, e.g., Kohler, G. et al. (1975) Nature 256:495-497; Kozbor, D. et al. (1985) J. Immunol. Methods 81:31-42; Cote, R.J. et al. (1983) Proc. Natl. Acad. Sci. USA 80:2026-2030; and Cole, S.P. et al. (1984) Mol. Cell Biol. 62:109-120.)

In addition, techniques developed for the production of "chimeric antibodies," such as the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used. (See, e.g., Morrison, S.L. et al. (1984) Proc. Natl. Acad. Sci. USA 81:6851-6855; Neuberger, M.S. et al. (1984) Nature 312:604-608; and Takeda, S. et al. (1985) Nature 314:452-454.) Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce CIRYP-specific single

chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries. (See, e.g., Burton, D.R. (1991) Proc. Natl. Acad. Sci. USA 88:10134-10137.)

Antibodies may also be produced by inducing in vivo production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature. (See, e.g., Orlandi, R. et al. (1989) Proc. Natl. Acad. Sci. USA 86:3833-3837; Winter, G. et al. (1991) Nature 349:293-299.)

Antibody fragments which contain specific binding sites for CIRYP may also be generated. For example, such fragments include, but are not limited to, F(ab')<sub>2</sub> fragments produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the F(ab')<sub>2</sub> fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity. (See, e.g., Huse, W.D. et al. (1989) Science 246:1275-1281.)

Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between CIRYP and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering CIRYP epitopes is generally used, but a competitive binding assay may also be employed (Pound, supra).

Various methods such as Scatchard analysis in conjunction with radioimmunoassay techniques may be used to assess the affinity of antibodies for CIRYP. Affinity is expressed as an association constant,  $K_a$ , which is defined as the molar concentration of CIRYP-antibody complex divided by the molar concentrations of free antigen and free antibody under equilibrium conditions. The  $K_a$  determined for a preparation of polyclonal antibodies, which are heterogeneous in their affinities for multiple CIRYP epitopes, represents the average affinity, or avidity, of the antibodies for CIRYP. The  $K_a$  determined for a preparation of monoclonal antibodies, which are monospecific for a particular CIRYP epitope, represents a true measure of affinity. High-affinity antibody preparations with  $K_a$  ranging from about  $10^9$  to  $10^{12}$  L/mole are preferred for use in immunoassays in which the CIRYP-antibody complex must withstand rigorous manipulations. Low-affinity antibody preparations with  $K_a$  ranging from about  $10^6$  to  $10^7$  L/mole are preferred for use in immunopurification and similar procedures which ultimately require dissociation of CIRYP, preferably in active form, from the antibody (Catty, D. (1988) Antibodies, Volume I: A Practical Approach, IRL Press, Washington, DC; Liddell, J.E. and Cryer, A. (1991) A Practical Guide to

Monoclonal Antibodies, John Wiley & Sons, New York NY).

The titer and avidity of polyclonal antibody preparations may be further evaluated to determine the quality and suitability of such preparations for certain downstream applications. For example, a polyclonal antibody preparation containing at least 1-2 mg specific antibody/ml, preferably 5-10 mg specific antibody/ml, is generally employed in procedures requiring precipitation of CIRYP-antibody complexes. Procedures for evaluating antibody specificity, titer, and avidity, and guidelines for antibody quality and usage in various applications, are generally available. (See, e.g., Catty, supra, and Coligan et al. supra.)

In another embodiment of the invention, the polynucleotides encoding CIRYP, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, the complement of the polynucleotide encoding CIRYP may be used in situations in which it would be desirable to block the transcription of the mRNA. In particular, cells may be transformed with sequences complementary to polynucleotides encoding CIRYP. Thus, complementary molecules or fragments may be used to modulate CIRYP activity, or to achieve regulation of gene function. Such technology is now well known in the art, and sense or antisense oligonucleotides or larger fragments can be designed from various locations along the coding or control regions of sequences encoding CIRYP.

Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. Methods which are well known to those skilled in the art can be used to construct vectors to express nucleic acid sequences complementary to the polynucleotides encoding CIRYP. (See, e.g., Sambrook, supra; Ausubel, 1995, supra.)

Genes encoding CIRYP can be turned off by transforming a cell or tissue with expression vectors which express high levels of a polynucleotide, or fragment thereof, encoding CIRYP. Such constructs may be used to introduce untranslatable sense or antisense sequences into a cell. Even in the absence of integration into the DNA, such vectors may continue to transcribe RNA molecules until they are disabled by endogenous nucleases. Transient expression may last for a month or more with a non-replicating vector, and may last even longer if appropriate replication elements are part of the vector system.

As mentioned above, modifications of gene expression can be obtained by designing complementary sequences or antisense molecules (DNA, RNA, or PNA) to the control, 5', or regulatory regions of the gene encoding CIRYP. Oligonucleotides derived from the transcription initiation site, e.g., between about positions -10 and +10 from the start site, may be employed. Similarly, inhibition can be achieved using triple helix base-pairing methodology. Triple helix pairing

is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature. (See, e.g., Gee, J.E. et al. (1994) in Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing, Mt. Kisco NY, pp. 163-177.) A complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. For example, engineered hammerhead motif ribozyme molecules may specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding CIRYP.

Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, including the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides, corresponding to the region of the target gene containing the cleavage site, may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

Complementary ribonucleic acid molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding CIRYP. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize complementary RNA, constitutively or inducibly, can be introduced into cell lines, cells, or tissues.

RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

Many methods for introducing vectors into cells or tissues are available and equally suitable

for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection, by liposome injections, or by polycationic amino polymers may be achieved using methods which are well known in the art. (See, e.g., Goldman, C.K. et al. (1997) Nat.

5 Biotechnol. 15:462-466.)

Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as humans, dogs, cats, cows, horses, rabbits, and monkeys.

10 An additional embodiment of the invention relates to the administration of a pharmaceutical or sterile composition, in conjunction with a pharmaceutically acceptable carrier, for any of the therapeutic effects discussed above. Such pharmaceutical compositions may consist of CIRYP, antibodies to CIRYP, and mimetics, agonists, antagonists, or inhibitors of CIRYP. The compositions may be administered alone or in combination with at least one other agent, such as a stabilizing compound, which may be administered in any sterile, biocompatible pharmaceutical carrier including,  
15 but not limited to, saline, buffered saline, dextrose, and water. The compositions may be administered to a patient alone, or in combination with other agents, drugs, or hormones.

The pharmaceutical compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal,  
20 enteral, topical, sublingual, or rectal means.

In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically-acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Further details on techniques for formulation and administration may be found in the latest edition of Remington's  
25 Pharmaceutical Sciences (Maack Publishing, Easton PA).

Pharmaceutical compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

30 Pharmaceutical preparations for oral use can be obtained through combining active compounds with solid excipient and processing the resultant mixture of granules (optionally, after grinding) to obtain tablets or dragee cores. Suitable auxiliaries can be added, if desired. Suitable excipients include carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, and sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose,

hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose; gums, including arabic and tragacanth; and proteins, such as gelatin and collagen. If desired, disintegrating or solubilizing agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, and alginic acid or a salt thereof, such as sodium alginate.

5 Dragee cores may be used in conjunction with suitable coatings, such as concentrated sugar solutions, which may also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, i.e., dosage.

10 Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with fillers or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or  
15 liquid polyethylene glycol with or without stabilizers.

Pharmaceutical formulations suitable for parenteral administration may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiologically buffered saline. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or  
20 dextran. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils, such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate, triglycerides, or liposomes. Non-lipid polycationic amino polymers may also be used for delivery. Optionally, the suspension may also contain suitable stabilizers or agents to increase the solubility of the compounds and allow for the preparation of  
25 highly concentrated solutions.

For topical or nasal administration, penetrants appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

The pharmaceutical compositions of the present invention may be manufactured in a manner that is known in the art, e.g., by means of conventional mixing, dissolving, granulating,  
30 dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes.

The pharmaceutical composition may be provided as a salt and can be formed with many acids, including but not limited to, hydrochloric, sulfuric, acetic, lactic, tartaric, malic, and succinic acids. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms. In other cases, the preparation may be a lyophilized powder which may contain any

or all of the following: 1 mM to 50 mM histidine, 0.1% to 2% sucrose, and 2% to 7% mannitol, at a pH range of 4.5 to 5.5, that is combined with buffer prior to use.

After pharmaceutical compositions have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. For administration of CIRYP, such  
5 labeling would include amount, frequency, and method of administration.

Pharmaceutical compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

For any compound, the therapeutically effective dose can be estimated initially either in cell  
10 culture assays, e.g., of neoplastic cells, or in animal models such as mice, rats, rabbits, dogs, or pigs. An animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

A therapeutically effective dose refers to that amount of active ingredient, for example  
15 CIRYP or fragments thereof, antibodies of CIRYP, and agonists, antagonists or inhibitors of CIRYP, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the  $ED_{50}$  (the dose therapeutically effective in 50% of the population) or  $LD_{50}$  (the dose lethal to 50% of the population) statistics. The dose ratio of toxic to therapeutic effects is the  
20 therapeutic index, which can be expressed as the  $LD_{50}/ED_{50}$  ratio. Pharmaceutical compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies are used to formulate a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that includes the  $ED_{50}$  with little or no toxicity. The dosage varies within this range depending upon the dosage form employed,  
25 the sensitivity of the patient, and the route of administration.

The exact dosage will be determined by the practitioner, in light of factors related to the subject requiring treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the  
30 subject, time and frequency of administration, drug combination(s), reaction sensitivities, and response to therapy. Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week, or biweekly depending on the half-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from about 0.1  $\mu$ g to 100,000  $\mu$ g, up to a total dose of



about 1 gram, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

## DIAGNOSTICS

In another embodiment, antibodies which specifically bind CIRYP may be used for the diagnosis of disorders characterized by expression of CIRYP, or in assays to monitor patients being treated with CIRYP or agonists, antagonists, or inhibitors of CIRYP. Antibodies useful for diagnostic purposes may be prepared in the same manner as described above for therapeutics. Diagnostic assays for CIRYP include methods which utilize the antibody and a label to detect CIRYP in human body fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by covalent or non-covalent attachment of a reporter molecule. A wide variety of reporter molecules, several of which are described above, are known in the art and may be used.

A variety of protocols for measuring CIRYP, including ELISAs, RIAs, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of CIRYP expression. Normal or standard values for CIRYP expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, for example, human subjects, with antibody to CIRYP under conditions suitable for complex formation. The amount of standard complex formation may be quantitated by various methods, such as photometric means. Quantities of CIRYP expressed in subject, control, and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

In another embodiment of the invention, the polynucleotides encoding CIRYP may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantify gene expression in biopsied tissues in which expression of CIRYP may be correlated with disease. The diagnostic assay may be used to determine absence, presence, and excess expression of CIRYP, and to monitor regulation of CIRYP levels during therapeutic intervention.

In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding CIRYP or closely related molecules may be used to identify nucleic acid sequences which encode CIRYP. The specificity of the probe, whether it is made from a highly specific region, e.g., the 5' regulatory region, or from a less specific region, e.g., a conserved motif, and the stringency of the hybridization or amplification will determine whether the probe identifies only naturally occurring sequences encoding CIRYP, allelic variants, or related

sequences.

Probes may also be used for the detection of related sequences, and may have at least 50% sequence identity to any of the CIRYP encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and may be derived from the sequence of SEQ ID NO:3-4 or from  
5 genomic sequences including promoters, enhancers, and introns of the CIRYP gene.

Means for producing specific hybridization probes for DNAs encoding CIRYP include the cloning of polynucleotide sequences encoding CIRYP or CIRYP derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA  
10 polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a variety of reporter groups, for example, by radionuclides such as  $^{32}\text{P}$  or  $^{35}\text{S}$ , or by enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

Polynucleotide sequences encoding CIRYP may be used for the diagnosis of disorders associated with expression of CIRYP. Examples of such disorders include, but are not limited to, a  
15 reproductive disorder, such as disorders of prolactin production, infertility (including tubal disease, ovulatory defects, and endometriosis), disruptions of the estrous cycle, disruptions of the menstrual cycle, polycystic ovary syndrome, ovarian hyperstimulation syndrome, endometrial and ovarian tumors, uterine fibroids, autoimmune disorders, ectopic pregnancies, teratogenesis, cancer of the breast, fibrocystic breast disease, galactorrhea, disruptions of spermatogenesis, abnormal sperm  
20 physiology, cancer of the testis, cancer of the prostate, benign prostatic hyperplasia, prostatitis, Peyronie's disease, impotence, carcinoma of the male breast, and gynecomastia; a gastrointestinal disorder, such as dysphagia, peptic esophagitis, esophageal spasm, esophageal stricture, esophageal carcinoma, dyspepsia, indigestion, gastritis, gastric carcinoma, anorexia, nausea, emesis, gastroparesis, antral or pyloric edema, abdominal angina, pyrosis, gastroenteritis, intestinal  
25 obstruction, infections of the intestinal tract, peptic ulcer, cholelithiasis, cholecystitis, cholestasis, pancreatitis, pancreatic carcinoma, biliary tract disease, hepatitis, hyperbilirubinemia, cirrhosis, passive congestion of the liver, hepatoma, infectious colitis, ulcerative colitis, ulcerative proctitis, Crohn's disease, Whipple's disease, Mallory-Weiss syndrome, colonic carcinoma, colonic obstruction, irritable bowel syndrome, short bowel syndrome, diarrhea, constipation, gastrointestinal  
30 hemorrhage, and acquired immunodeficiency syndrome (AIDS) enteropathy; a neuronal disorder, such as akathisia, Alzheimer's disease, amnesia, amyotrophic lateral sclerosis, bipolar disorder, catatonia, cerebral neoplasms, dementia, depression, diabetic neuropathy, Down's syndrome, tardive dyskinesia, dystonias, epilepsy, Huntington's disease, peripheral neuropathy, multiple sclerosis, neurofibromatosis, Parkinson's disease, paranoid psychoses, postherpetic neuralgia, schizophrenia,

seasonal affective disorder (SAD), and Tourette's disorder; and a developmental disorder, such as renal tubular acidosis, anemia, Cushing's syndrome, achondroplastic dwarfism, Duchenne and Becker muscular dystrophy, epilepsy, gonadal dysgenesis, WAGR syndrome (Wilms' tumor, aniridia, genitourinary abnormalities, and mental retardation), Smith-Magenis syndrome, myelodysplastic syndrome, hereditary mucoepithelial dysplasia, hereditary keratodermas, hereditary neuropathies such as Charcot-Marie-Tooth disease and neurofibromatosis, hypothyroidism, hydrocephalus, seizure disorders such as Sydenham's chorea and cerebral palsy, spina bifida, anencephaly, craniorachischisis, congenital glaucoma, cataract, and sensorineural hearing loss. The polynucleotide sequences encoding CIRYP may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; in dipstick, pin, and multiformat ELISA-like assays; and in microarrays utilizing fluids or tissues from patients to detect altered CIRYP expression. Such qualitative or quantitative methods are well known in the art.

In a particular aspect, the nucleotide sequences encoding CIRYP may be useful in assays that detect the presence of associated disorders, particularly those mentioned above. The nucleotide sequences encoding CIRYP may be labeled by standard methods and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantified and compared with a standard value. If the amount of signal in the patient sample is significantly altered in comparison to a control sample then the presence of altered levels of nucleotide sequences encoding CIRYP in the sample indicates the presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or to monitor the treatment of an individual patient.

In order to provide a basis for the diagnosis of a disorder associated with expression of CIRYP, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, encoding CIRYP, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with values from an experiment in which a known amount of a substantially purified polynucleotide is used. Standard values obtained in this manner may be compared with values obtained from samples from patients who are symptomatic for a disorder. Deviation from standard values is used to establish the presence of a disorder.

Once the presence of a disorder is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate that which is observed in the normal subject. The results obtained from

successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

With respect to cancer, the presence of an abnormal amount of transcript (either under- or overexpressed) in biopsied tissue from an individual may indicate a predisposition for the  
5 development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Additional diagnostic uses for oligonucleotides designed from the sequences encoding  
10 CIRYP may involve the use of PCR. These oligomers may be chemically synthesized, generated enzymatically, or produced in vitro. Oligomers will preferably contain a fragment of a polynucleotide encoding CIRYP, or a fragment of a polynucleotide complementary to the polynucleotide encoding CIRYP, and will be employed under optimized conditions for identification of a specific gene or condition. Oligomers may also be employed under less stringent conditions for detection or  
15 quantification of closely related DNA or RNA sequences.

Methods which may also be used to quantify the expression of CIRYP include radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and interpolating results from standard curves. (See, e.g., Melby, P.C. et al. (1993) J. Immunol. Methods 159:235-244; Duplaa, C. et al. (1993) Anal. Biochem. 212:229-236.) The speed of quantitation of multiple samples may be  
20 accelerated by running the assay in a high-throughput format where the oligomer of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation.

In further embodiments, oligonucleotides or longer fragments derived from any of the polynucleotide sequences described herein may be used as targets in a microarray. The microarray  
25 can be used to monitor the expression level of large numbers of genes simultaneously and to identify genetic variants, mutations, and polymorphisms. This information may be used to determine gene function, to understand the genetic basis of a disorder, to diagnose a disorder, and to develop and monitor the activities of therapeutic agents.

Microarrays may be prepared, used, and analyzed using methods known in the art. (See, e.g.,  
30 Brennan, T.M. et al. (1995) U.S. Patent No. 5,474,796; Schena, M. et al. (1996) Proc. Natl. Acad. Sci. USA 93:10614-10619; Baldeschweiler et al. (1995) PCT application WO95/251116; Shalon, D. et al. (1995) PCT application WO95/35505; Heller, R.A. et al. (1997) Proc. Natl. Acad. Sci. USA 94:2150-2155; and Heller, M.J. et al. (1997) U.S. Patent No. 5,605,662.)

In another embodiment of the invention, nucleic acid sequences encoding CIRYP may be

used to generate hybridization probes useful in mapping the naturally occurring genomic sequence. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome, or to artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions, or single chromosome cDNA libraries. (See, e.g., Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355; Price, C.M. (1993) Blood Rev. 7:127-134; and Trask, B.J. (1991) Trends Genet. 7:149-154.)

Fluorescent in situ hybridization (FISH) may be correlated with other physical chromosome mapping techniques and genetic map data. (See, e.g., Heinz-Ulrich, et al. (1995) in Meyers, supra, pp. 965-968.) Examples of genetic map data can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMIM) World Wide Web site. Correlation between the location of the gene encoding CIRYP on a physical chromosomal map and a specific disorder, or a predisposition to a specific disorder, may help define the region of DNA associated with that disorder. The nucleotide sequences of the invention may be used to detect differences in gene sequences among normal, carrier, and affected individuals.

In situ hybridization of chromosomal preparations and physical mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the number or arm of a particular human chromosome is not known. New sequences can be assigned to chromosomal arms by physical mapping. This provides valuable information to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the disease or syndrome has been crudely localized by genetic linkage to a particular genomic region, e.g., ataxia-telangiectasia to 11q22-23, any sequences mapping to that area may represent associated or regulatory genes for further investigation. (See, e.g., Gatti, R.A. et al. (1988) Nature 336:577-580.) The nucleotide sequence of the subject invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc., among normal, carrier, or affected individuals.

In another embodiment of the invention, CIRYP, its catalytic or immunogenic fragments, or oligopeptides thereof can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes between CIRYP and the agent being tested may be measured.

Another technique for drug screening provides for high throughput screening of compounds having suitable binding affinity to the protein of interest. (See, e.g., Geysen, et al. (1984) PCT application WO84/03564.) In this method, large numbers of different small test compounds are

synthesized on a solid substrate. The test compounds are reacted with CIRYP, or fragments thereof, and washed. Bound CIRYP is then detected by methods well known in the art. Purified CIRYP can also be coated directly onto plates for use in the aforementioned drug screening techniques.

Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a  
5 solid support.

In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding CIRYP specifically compete with a test compound for binding CIRYP. In this manner, antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with CIRYP.

10 In additional embodiments, the nucleotide sequences which encode CIRYP may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

Without further elaboration, it is believed that one skilled in the art can, using the preceding  
15 description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

The disclosures of all patents, applications, and publications mentioned above and below, in particular U.S. Ser. No. [Attorney Docket No. PF-0659 P, filed January 15, 1999], are hereby  
20 expressly incorporated by reference.

## EXAMPLES

### I. Construction of cDNA Libraries

The DUODNOT01 library was constructed using RNA isolated from duodenal tissue  
25 obtained from a 41-year-old Caucasian female during a radical pancreaticoduodenectomy. Family history included benign hypertension and malignant skin neoplasm.

The UTRSNOT02 library was constructed using RNA isolated from uterine tissue obtained from a 34-year-old Caucasian female during a vaginal hysterectomy. Patient history included mitral valve disorder. Family history included stomach cancer, congenital heart anomaly, irritable bowel  
30 syndrome, ulcerative colitis, colon cancer, cerebrovascular disease, type II diabetes, and depression.

RNA was purchased from Clontech or isolated from tissues described above. Some tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized and lysed in phenol or in a suitable mixture of denaturants, such as TRIZOL (Life Technologies), a monophasic solution of phenol and guanidine isothiocyanate. The resulting lysates were centrifuged

over CsCl cushions or extracted with chloroform. RNA was precipitated from the lysates with either isopropanol or sodium acetate and ethanol, or by other routine methods.

Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA purity. In some cases, RNA was treated with DNase. For most libraries, poly(A+) RNA was isolated using oligo d(T)-coupled paramagnetic particles (Promega), OLIGOTEX latex particles (QIAGEN, Chatsworth CA), or an OLIGOTEX mRNA purification kit (QIAGEN). Alternatively, RNA was isolated directly from tissue lysates using other RNA isolation kits, e.g., the POLY(A)PURE mRNA purification kit (Ambion, Austin TX).

In some cases, Stratagene was provided with RNA and constructed the corresponding cDNA libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed with the UNIZAP vector system (Stratagene) or SUPERScript plasmid system (Life Technologies), using the recommended procedures or similar methods known in the art. (See, e.g., Ausubel, 1997, supra, units 5.1-6.6.) Reverse transcription was initiated using oligo d(T) or random primers. Synthetic oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA was digested with the appropriate restriction enzyme or enzymes. For most libraries, the cDNA was size-selected (300-1000 bp) using SEPHACRYL S1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column chromatography (Amersham Pharmacia Biotech) or preparative agarose gel electrophoresis. cDNAs were ligated into compatible restriction enzyme sites of the polylinker of a suitable plasmid, e.g., PBLUESCRIPT plasmid (Stratagene), PSPORT1 plasmid (Life Technologies), or pINCY (Incyte Pharmaceuticals, Palo Alto CA). Recombinant plasmids were transformed into competent *E. coli* cells including XL1-Blue, XL1-BlueMRF, or SOLR from Stratagene or DH5 $\alpha$ , DH10B, or ElectroMAX DH10B from Life Technologies.

## II. Isolation of cDNA Clones

Plasmids were recovered from host cells by in vivo excision using the UNIZAP vector system (Stratagene) or by cell lysis. Plasmids were purified using at least one of the following: a Magic or WIZARD Minipreps DNA purification system (Promega); an AGTC Miniprep purification kit (Edge Biosystems, Gaithersburg MD); and QIAWELL 8 Plasmid, QIAWELL 8 Plus Plasmid, QIAWELL 8 Ultra Plasmid purification systems or the R.E.A.L. PREP 96 plasmid purification kit from QIAGEN. Following precipitation, plasmids were resuspended in 0.1 ml of distilled water and stored, with or without lyophilization, at 4°C.

Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a high-throughput format (Rao, V.B. (1994) Anal. Biochem. 216:1-14). Host cell lysis and thermal cycling steps were carried out in a single reaction mixture. Samples were processed and stored in 384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically

using PICOGREEN dye (Molecular Probes, Eugene OR) and a FLUOROSKAN II fluorescence scanner (Labsystems Oy, Helsinki, Finland).

### III. Sequencing and Analysis

cDNA sequencing reactions were processed using standard methods or high-throughput instrumentation such as the ABI CATALYST 800 (Perkin-Elmer) thermal cyclor or the PTC-200 thermal cyclor (MJ Research) in conjunction with the HYDRA microdispenser (Robbins Scientific) or the MICROLAB 2200 (Hamilton) liquid transfer system. cDNA sequencing reactions were prepared using reagents provided by Amersham Pharmacia Biotech or supplied in ABI sequencing kits such as the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Perkin-Elmer).

Electrophoretic separation of cDNA sequencing reactions and detection of labeled polynucleotides were carried out using the MEGABACE 1000 DNA sequencing system (Molecular Dynamics); the ABI PRISM 373 or 377 sequencing system (Perkin-Elmer) in conjunction with standard ABI protocols and base calling software; or other sequence analysis systems known in the art. Reading frames within the cDNA sequences were identified using standard methods (reviewed in Ausubel, 1997, supra, unit 7.7). Some of the cDNA sequences were selected for extension using the techniques disclosed in Example V.

The polynucleotide sequences derived from cDNA sequencing were assembled and analyzed using a combination of software programs which utilize algorithms well known to those skilled in the art. Table 1 summarizes the tools, programs, and algorithms used and provides applicable descriptions, references, and threshold parameters. The first column of Table 1 shows the tools, programs, and algorithms used, the second column provides brief descriptions thereof, the third column presents appropriate references, all of which are incorporated by reference herein in their entirety, and the fourth column presents, where applicable, the scores, probability values, and other parameters used to evaluate the strength of a match between two sequences (the higher the score, the greater the homology between two sequences). Sequences were analyzed using MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco CA) and LASERGENE software (DNASTAR). Polynucleotide and polypeptide sequence alignments were generated using the default parameters specified by the clustal algorithm as incorporated into the MEGALIGN multisequence alignment program (DNASTAR), which also calculates the percent identity between aligned sequences.

The polynucleotide sequences were validated by removing vector, linker, and polyA sequences and by masking ambiguous bases, using algorithms and programs based on BLAST, dynamic programming, and dinucleotide nearest neighbor analysis. The sequences were then queried against a selection of public databases such as the GenBank primate, rodent, mammalian, vertebrate,



and eukaryote databases, and BLOCKS, PRINTS, DOMO, PRODOM, and PFAM to acquire annotation using programs based on BLAST, FASTA, and BLIMPS. The sequences were assembled into full length polynucleotide sequences using programs based on Phred, Phrap, and Consed, and were screened for open reading frames using programs based on GeneMark, BLAST, and FASTA.

- 5 The full length polynucleotide sequences were translated to derive the corresponding full length amino acid sequences, and these full length sequences were subsequently analyzed by querying against databases such as the GenBank databases (described above), SwissProt, BLOCKS, PRINTS, DOMO, PRODOM, Prosite, and Hidden Markov Model (HMM)-based protein family databases such as PFAM. HMM is a probabilistic approach which analyzes consensus primary structures of gene
- 10 families. (See, e.g., Eddy, S.R. (1996) Curr. Opin. Struct. Biol. 6:361-365.)

The programs described above for the assembly and analysis of full length polynucleotide and amino acid sequences were also used to identify polynucleotide sequence fragments from SEQ ID NO:3-4. Fragments from about 20 to about 4000 nucleotides which are useful in hybridization and amplification technologies were described in The Invention section above.

#### 15 IV. Northern Analysis

Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound. (See, e.g., Sambrook, supra, ch. 7; Ausubel, 1995, supra, ch. 4 and 16.)

- 20 Analogous computer techniques applying BLAST were used to search for identical or related molecules in nucleotide databases such as GenBank or LIFESEQ (Incyte Pharmaceuticals). This analysis is much faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or similar. The basis of the search is the product score, which is defined as:

$$25 \quad \frac{\% \text{ sequence identity} \times \% \text{ maximum BLAST score}}{100}$$

- The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. For example, with a product score of 40, the match will be exact within a 1% to 2% error, and, with a product score of 70, the match will be exact. Similar molecules are
- 30 usually identified by selecting those which show product scores between 15 and 40, although lower scores may identify related molecules.

The results of northern analyses are reported as a percentage distribution of libraries in which the transcript encoding CIRYP occurred. Analysis involved the categorization of cDNA libraries by organ/tissue and disease. The organ/tissue categories included cardiovascular, dermatologic,



the sequence.

The extended nucleotides were desalted and concentrated, transferred to 384-well plates, digested with CviJI cholera virus endonuclease (Molecular Biology Research, Madison WI), and sonicated or sheared prior to religation into pUC 18 vector (Amersham Pharmacia Biotech). For  
5 shotgun sequencing, the digested nucleotides were separated on low concentration (0.6 to 0.8%) agarose gels, fragments were excised, and agar digested with Agar ACE (Promega). Extended clones were religated using T4 ligase (New England Biolabs, Beverly MA) into pUC 18 vector (Amersham Pharmacia Biotech), treated with Pfu DNA polymerase (Stratagene) to fill-in restriction site overhangs, and transfected into competent *E. coli* cells. Transformed cells were selected on  
10 antibiotic-containing media, individual colonies were picked and cultured overnight at 37°C in 384-well plates in LB/2x carb liquid media.

The cells were lysed, and DNA was amplified by PCR using Taq DNA polymerase (Amersham Pharmacia Biotech) and Pfu DNA polymerase (Stratagene) with the following parameters: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 72°C, 2 min;  
15 Step 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72°C, 5 min; Step 7: storage at 4°C. DNA was quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA recoveries were reamplified using the same conditions as described above. Samples were diluted with 20% dimethylsulfoxide (1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIRECT kit (Amersham Pharmacia Biotech) or the ABI PRISM  
20 BIGDYE Terminator cycle sequencing ready reaction kit (Perkin-Elmer).

In like manner, the nucleotide sequences of SEQ ID NO:3-4 are used to obtain 5' regulatory sequences using the procedure above, oligonucleotides designed for such extension, and an appropriate genomic library.

#### **VI. Labeling and Use of Individual Hybridization Probes**

25 Hybridization probes derived from SEQ ID NO:3-4 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base pairs, is specifically described, essentially the same procedure is used with larger nucleotide fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 software (National Biosciences) and labeled by combining 50 pmol of each oligomer, 250  $\mu$ Ci of [ $\gamma$ -<sup>32</sup>P] adenosine  
30 triphosphate (Amersham Pharmacia Biotech), and T4 polynucleotide kinase (DuPont NEN, Boston MA). The labeled oligonucleotides are substantially purified using a SEPHADEX G-25 superfine size exclusion dextran bead column (Amersham Pharmacia Biotech). An aliquot containing 10<sup>7</sup> counts per minute of the labeled probe is used in a typical membrane-based hybridization analysis of human genomic DNA digested with one of the following endonucleases: Ase I, Bgl II, Eco RI, Pst I,

Xba I, or Pvu II (DuPont NEN).

The DNA from each digest is fractionated on a 0.7% agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under conditions of up to, for example, 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate. Hybridization patterns are visualized using autoradiography or an alternative imaging means and compared.

#### VII. Microarrays

A chemical coupling procedure and an ink jet device can be used to synthesize array elements on the surface of a substrate. (See, e.g., Baldeschweiler, supra.) An array analogous to a dot or slot blot may also be used to arrange and link elements to the surface of a substrate using thermal, UV, chemical, or mechanical bonding procedures. A typical array may be produced by hand or using available methods and machines and contain any appropriate number of elements. After hybridization, nonhybridized probes are removed and a scanner used to determine the levels and patterns of fluorescence. The degree of complementarity and the relative abundance of each probe which hybridizes to an element on the microarray may be assessed through analysis of the scanned images.

Full-length cDNAs, Expressed Sequence Tags (ESTs), or fragments thereof may comprise the elements of the microarray. Fragments suitable for hybridization can be selected using software well known in the art such as LASERGENE software (DNASTAR). Full-length cDNAs, ESTs, or fragments thereof corresponding to one of the nucleotide sequences of the present invention, or selected at random from a cDNA library relevant to the present invention, are arranged on an appropriate substrate, e.g., a glass slide. The cDNA is fixed to the slide using, e.g., UV cross-linking followed by thermal and chemical treatments and subsequent drying. (See, e.g., Schena, M. et al. (1995) Science 270:467-470; Shalon, D. et al. (1996) Genome Res. 6:639-645.) Fluorescent probes are prepared and used for hybridization to the elements on the substrate. The substrate is analyzed by procedures described above.

#### VIII. Complementary Polynucleotides

Sequences complementary to the CIRYP-encoding sequences, or any parts thereof, are used to detect, decrease, or inhibit expression of naturally occurring CIRYP. Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with smaller or with larger sequence fragments. Appropriate oligonucleotides are designed using OLIGO 4.06 software (National Biosciences) and the coding sequence of CIRYP. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5' sequence

and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the CIRYP-encoding transcript.

#### IX. Expression of CIRYP

Expression and purification of CIRYP is achieved using bacterial or virus-based expression systems. For expression of CIRYP in bacteria, cDNA is subcloned into an appropriate vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA transcription. Examples of such promoters include, but are not limited to, the *trp-lac* (*tac*) hybrid promoter and the T5 or T7 bacteriophage promoter in conjunction with the *lac* operator regulatory element. Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21(DE3). Antibiotic resistant bacteria express CIRYP upon induction with isopropyl beta-D-thiogalactopyranoside (IPTG). Expression of CIRYP in eukaryotic cells is achieved by infecting insect or mammalian cell lines with recombinant Autographica californica nuclear polyhedrosis virus (AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is replaced with cDNA encoding CIRYP by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription. Recombinant baculovirus is used to infect Spodoptera frugiperda (Sf9) insect cells in most cases, or human hepatocytes, in some cases. Infection of the latter requires additional genetic modifications to baculovirus. (See Engelhard, E.K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945.)

In most expression systems, CIRYP is synthesized as a fusion protein with, e.g., glutathione S-transferase (GST) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step, affinity-based purification of recombinant fusion protein from crude cell lysates. GST, a 26-kilodalton enzyme from Schistosoma japonicum, enables the purification of fusion proteins on immobilized glutathione under conditions that maintain protein activity and antigenicity (Amersham Pharmacia Biotech). Following purification, the GST moiety can be proteolytically cleaved from CIRYP at specifically engineered sites. FLAG, an 8-amino acid peptide, enables immunoaffinity purification using commercially available monoclonal and polyclonal anti-FLAG antibodies (Eastman Kodak). 6-His, a stretch of six consecutive histidine residues, enables purification on metal-chelate resins (QIAGEN). Methods for protein expression and purification are discussed in Ausubel (1995, supra, ch. 10 and 16). Purified CIRYP obtained by these methods can be used directly in the following activity assay.

#### X. Demonstration of CIRYP Activity

An electro-mobility shift assay (EMSA) demonstrates CIRYP activity by measuring CIRYP

transcriptional activation in response to varying light and dark conditions. EMSA can be used for detecting DNA-protein complexes whereby a radioactively or chemically labeled DNA sequence is incubated with a particular protein. The resultant complex is resolved on a polyacrylamide gel and visualized by autoradiography. When animals are placed in constant dark, DNA binding activity to promoter regions of certain circadian rhythm associated genes is reduced. Consequently, the binding of transcriptional activators to promoter regions of CIRYP is predicted to differ depending on the amount of light exposure, and would be directly proportional to CIRYP activity.

#### **XI. Functional Assays**

CIRYP function is assessed by expressing the sequences encoding CIRYP at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned into a mammalian expression vector containing a strong promoter that drives high levels of cDNA expression. Vectors of choice include pCMV SPORT (Life Technologies) and pCR3.1 (Invitrogen, Carlsbad CA), both of which contain the cytomegalovirus promoter. 5-10  $\mu$ g of recombinant vector are transiently transfected into a human cell line, for example, an endothelial or hematopoietic cell line, using either liposome formulations or electroporation. 1-2  $\mu$ g of an additional plasmid containing sequences encoding a marker protein are co-transfected. Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP; Clontech), CD64, or a CD64-GFP fusion protein. Flow cytometry (FCM), an automated, laser optics-based technique, is used to identify transfected cells expressing GFP or CD64-GFP and to evaluate the apoptotic state of the cells and other cellular properties. FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as measured by staining of DNA with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface. Methods in flow cytometry are discussed in Ormerod, M.G. (1994) Flow Cytometry, Oxford, New York NY.

The influence of CIRYP on gene expression can be assessed using highly purified populations of cells transfected with sequences encoding CIRYP and either CD64 or CD64-GFP. CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved regions of human immunoglobulin G (IgG). Transfected cells are efficiently separated from nontransfected cells using magnetic beads coated with either human IgG or antibody against CD64 (DYNAL, Lake

Success NY). mRNA can be purified from the cells using methods well known by those of skill in the art. Expression of mRNA encoding CIRYP and other genes of interest can be analyzed by northern analysis or microarray techniques.

## **XII. Production of CIRYP Specific Antibodies**

5 CIRYP substantially purified using polyacrylamide gel electrophoresis (PAGE; see, e.g., Harrington, M.G. (1990) *Methods Enzymol.* 182:488-495), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols.

Alternatively, the CIRYP amino acid sequence is analyzed using LASERGENE software (DNASTAR) to determine regions of high immunogenicity, and a corresponding oligopeptide is  
10 synthesized and used to raise antibodies by means known to those of skill in the art. Methods for selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well described in the art. (See, e.g., Ausubel, 1995, *supra*, ch. 11.)

Typically, oligopeptides of about 15 residues in length are synthesized using an ABI 431A peptide synthesizer (Perkin-Elmer) using fmoc-chemistry and coupled to KLH (Sigma-Aldrich, St.  
15 Louis MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to increase immunogenicity. (See, e.g., Ausubel, 1995, *supra*.) Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. Resulting antisera are tested for antipeptide and anti-CIRYP activity by, for example, binding the peptide or CIRYP to a substrate, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG.

## **20 XIII. Purification of Naturally Occurring CIRYP Using Specific Antibodies**

Naturally occurring or recombinant CIRYP is substantially purified by immunoaffinity chromatography using antibodies specific for CIRYP. An immunoaffinity column is constructed by covalently coupling anti-CIRYP antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is  
25 blocked and washed according to the manufacturer's instructions.

Media containing CIRYP are passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of CIRYP (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/CIRYP binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such  
30 as urea or thiocyanate ion), and CIRYP is collected.

## **XIV. Identification of Molecules Which Interact with CIRYP**

CIRYP, or biologically active fragments thereof, are labeled with <sup>125</sup>I Bolton-Hunter reagent. (See, e.g., Bolton A.E. and W.M. Hunter (1973) *Biochem. J.* 133:529-539.) Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled CIRYP, washed,

and any wells with labeled CIRYP complex are assayed. Data obtained using different concentrations of CIRYP are used to calculate values for the number, affinity, and association of CIRYP with the candidate molecules.

- 5           Various modifications and variations of the described methods and systems of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with certain embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are
- 10   obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.



Table 1

Program	Description	Reference	Parameter Threshold
ABI FACTURA	A program that removes vector sequences and masks ambiguous bases in nucleic acid sequences.	Perkin-Elmer Applied Biosystems, Foster City, CA.	
ABI/PARACEL FDF	A Fast Data Finder useful in comparing and annotating amino acid or nucleic acid sequences.	Perkin-Elmer Applied Biosystems, Foster City, CA; Paracel Inc., Pasadena, CA.	Mismatch <50%
ABI AutoAssembler	A program that assembles nucleic acid sequences.	Perkin-Elmer Applied Biosystems, Foster City, CA.	
BLAST	A Basic Local Alignment Search Tool useful in sequence similarity search for amino acid and nucleic acid sequences. BLAST includes five functions: blastp, blastn, blastx, tblastn, and tblastx.	Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410; Altschul, S.F. et al. (1997) Nucleic Acids Res. 25: 3389-3402.	ESTs: Probability value= 1.0E-8 or less Full Length sequences: Probability value= 1.0E-10 or less
FASTA	A Pearson and Lipman algorithm that searches for similarity between a query sequence and a group of sequences of the same type. FASTA comprises at least five functions: fasta, tfasta, fastx, tfastx, and ssearch.	Pearson, W.R. and D.J. Lipman (1988) Proc. Natl. Acad. Sci. 85:2444-2448; Pearson, W.R. (1990) Methods Enzymol. 183: 63-98; and Smith, T.F. and M. S. Waterman (1981) Adv. Appl. Math. 2:482-489.	ESTs: fasta E value=1.06E-6 Assembled ESTs: fasta Identity= 95% or greater and Match length=200 bases or greater, fastx E value=1.0E-8 or less Full Length sequences: fastx score=100 or greater
BLIMPS	A BLOCKS IMProved Searcher that matches a sequence against those in BLOCKS, PRINTS, DOMO, PRODOM, and PFAM databases to search for gene families, sequence homology, and structural fingerprint regions.	Henikoff, S. and J.G. Henikoff, Nucl. Acid Res., 19:6565-72, 1991. J.G. Henikoff and S. Henikoff (1996) Methods Enzymol. 266:88-105; and Attwood, T.K. et al. (1997) J. Chem. Inf. Comput. Sci. 37: 417-424.	Score=1000 or greater, Ratio of Score/Strength = 0.75 or larger; and, if applicable, Probability value= 1.0E-3 or less
HMMER	An algorithm for searching a query sequence against hidden Markov model (HMM)-based databases of protein family consensus sequences, such as PFAM.	Krogh, A. et al. (1994) J. Mol. Biol., 235:1501-1531; Sonnhammer, E.L.L. et al. (1988) Nucleic Acids Res. 26:320-322.	Score=10-50 bits for PFAM hits, depending on individual protein families

Table 1 (cont.)

Program	Description	Reference	Parameter Threshold
ProfileScan	An algorithm that searches for structural and sequence motifs in protein sequences that match sequence patterns defined in Prosite.	Gribskov, M. et al. (1988) CABIOS 4:61-66; Gribskov, et al. (1989) Methods Enzymol. 183:146-159; Bairoch, A. et al. (1997) Nucleic Acids Res. 25: 217-221.	Normalized quality score $\geq$ GCG-specified "HIGH" value for that particular Prosite motif. Generally, score=1.4-2.1.
Phred	A base-calling algorithm that examines automated sequencer traces with high sensitivity and probability.	Ewing, B. et al. (1998) Genome Res. 8:175-185; Ewing, B. and P. Green (1998) Genome Res. 8:186-194.	
Phrap	A Phils Revised Assembly Program including SWAT and CrossMatch, programs based on efficient implementation of the Smith-Waterman algorithm, useful in searching sequence homology and assembling DNA sequences.	Smith, T.F. and M. S. Waterman (1981) Adv. Appl. Math. 2:482-489; Smith, T.F. and M. S. Waterman (1981) J. Mol. Biol. 147:195-197; and Green, P., University of Washington, Seattle, WA.	Score= 120 or greater; Match length= 56 or greater
Consed	A graphical tool for viewing and editing Phrap assemblies	Gordon, D. et al. (1998) Genome Res. 8:195-202.	
SPScan	A weight matrix analysis program that scans protein sequences for the presence of secretory signal peptides.	Nielson, H. et al. (1997) Protein Engineering 10:1-6; Claverie, J.M. and S. Audic (1997) CABIOS 12: 431-439.	Score=3.5 or greater
Motifs	A program that searches amino acid sequences for patterns that matched those defined in Prosite.	Bairoch et al. <u>supra</u> ; Wisconsin Package Program Manual, version 9, page M51-59, Genetics Computer Group, Madison, WI.	

What is claimed is:

1. An isolated polypeptide comprising:
  - a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-2,
  - 5 b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-2,
  - c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-2, or
  - d) an immunogenic fragment of an amino acid sequence selected from the group consisting  
10 of SEQ ID NO:1-2.
2. An isolated polypeptide of claim 1, having an amino acid sequence selected from the group consisting of SEQ ID NO:1-2.
- 15 3. An isolated polynucleotide encoding a polypeptide of claim 1.
4. An isolated polynucleotide of claim 3, having a sequence selected from the group consisting of SEQ ID NO:3-4.
- 20 5. A recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide of claim 3.
6. A cell transformed with a recombinant polynucleotide of claim 5.
- 25 7. A transgenic organism comprising a polynucleotide of claim 5.
8. A method for producing a polypeptide of claim 1, the method comprising:
  - a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide, and said recombinant polynucleotide  
30 comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim 1, and
  - b) recovering the polypeptide so expressed.
9. An isolated antibody which specifically binds to a polypeptide of claim 1.

10. An isolated polynucleotide comprising:
- a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:3-4,
  - b) a naturally occurring polynucleotide sequence having at least 70% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:3-4,
  - 5 c) a polynucleotide sequence complementary to a), or
  - d) a polynucleotide sequence complementary to b).
11. An isolated polynucleotide comprising at least 60 contiguous nucleotides of a polynucleotide of claim 10.
- 10 12. A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 10, the method comprising:
- a) hybridizing the sample with a probe comprising at least 16 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe
  - 15 specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide, and
  - b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.
- 20 13. A method of claim 12, wherein the probe comprises at least 30 contiguous nucleotides.
14. A method of claim 12, wherein the probe comprises at least 60 contiguous nucleotides.
15. A pharmaceutical composition comprising an effective amount of a polypeptide of claim
- 25 1 and a pharmaceutically acceptable excipient.
16. A method of treating a disease or condition associated with decreased expression of functional CIRYP, comprising administering to a patient in need of such treatment the pharmaceutical composition of claim 15.
- 30 17. A method for screening a compound for effectiveness as an agonist of a polypeptide of claim 1, the method comprising:
- a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
  - b) detecting agonist activity in the sample.

18. A pharmaceutical composition comprising an agonist compound identified by a method of claim 17 and a pharmaceutically acceptable excipient.

19. A method of treating a disease or condition associated with decreased expression of functional CIRYP, comprising administering to a patient in need of such treatment a pharmaceutical composition of claim 18.

20. A method for screening a compound for effectiveness as an antagonist of a polypeptide of claim 1, the method comprising:

- a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
- b) detecting antagonist activity in the sample.

21. A pharmaceutical composition comprising an antagonist compound identified by a method of claim 20 and a pharmaceutically acceptable excipient.

22. A method for treating a disease or condition associated with overexpression of functional CIRYP, comprising administering to a patient in need of such treatment a pharmaceutical composition of claim 21.

23. A method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence of claim 4, the method comprising:

- a) exposing a sample comprising the target polynucleotide to a compound, and
- b) detecting altered expression of the target polynucleotide.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
20 July 2000 (20.07.2000)

PCT

(10) International Publication Number  
WO 00/42172 A3

(51) International Patent Classification<sup>7</sup>: C12N 5/10,  
C07K 14/47, C12N 15/10, 15/63, C07K 16/18, A01K  
67/027, G01N 33/48

(US). AZIMZAI, Yalda [US/US]; 2045 Rock Springs  
Drive, Hayward, CA 94545 (US).

(21) International Application Number: PCT/US00/01086

(74) Agents: HAMLET-COX, Diana et al.; Incyte Pharma-  
ceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304  
(US).

(22) International Filing Date: 14 January 2000 (14.01.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/183,019 15 January 1999 (15.01.1999) US

(81) Designated States (*national*): AL, AM, AT, AU, AZ, BA,  
BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES,  
FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG,  
MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,  
SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN,  
YU, ZW.

(63) Related by continuation (CON) or continuation-in-part  
(CIP) to earlier application:  
US 60/183,019 (CIP)  
Filed on 15 January 1999 (15.01.1999)

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent  
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent  
(AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU,  
MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): INCYTE  
PHARMACEUTICALS, INC. [US/US]; 3174 Porter  
Drive, Palo Alto, CA 94304 (US).

Published:  
— With international search report.

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): HILLMAN, Jen-  
nifer, L. [US/US]; 230 Monroe Drive #12, Mountain View,  
CA 94040 (US). TANG, Y., Tom [CH/US]; 4230 Ranwick  
Court, San Jose, CA 95118 (US). LU, Dyung, Aina, M.  
[US/US]; 55 Park Belmont Place, San Jose, CA 95136

(88) Date of publication of the international search report:  
30 November 2000

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: HUMAN HOMOLOGUES OF PROTEINS REGULATED BY CIRCADIAN RHYTHMS

(57) Abstract: The invention provides human proteins associated with circadian rhythms (CIRYP) and polynucleotides which identify and encode CIRYP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of CIRYP.

WO 00/42172 A3

5' CTG CGT CAG GTC CGG GCT CCT GGA CTT CGC CTT TCC CGA GCC CTG GAG GTG GGG 56  
11 20 29 38 47  
65 65 GGT TCA CCA ATT TTT AAA ATC CAA ATA TAT CTC ATG GTA CAG TGG AAG 110  
74 83 92 101  
119 119 CCA GAG AGT CTG GAA GTT TGG GTT CTG GTC TCG GCT GTG CCA CTG ACT 164  
128 137 146 155  
173 173 GAC CTT GGG ATC TTG TGC TGT GAA GAC ATT TCC CAA GTG CTT CAT GTT 218  
182 191 200 209  
227 227 CAG CAA ATC TGA CCC ACA AGG CCT GGA AAG AGG TGA TTG TTA GGT TGC GCA 272  
236 245 254 263  
281 281 GTC TTA TCC AGC TCA GCT TCC CCT GGG ACC CAC CGT GGG ACC TGA GGC 326  
290 308 317  
335 335 GGG GTG GAC TTG GCC TCC TCC ATG GCA CAC CGG CTG CAG ATA CGA CTG 380  
344 353 362 371 380  
M A H R L Q I R L

FIGURE 1A

389 CTG ACG TGG GAT GTG AAG GAC ACG CTG CTC AGG CTC 416 425 434  
 L T W D V K AAG GAC ACG CTG CTC AGG CTC CGC CAC CCC TTA GGG GAG  
 398 407  
 443 GCC TAT GCC ACC AAG GCC CGG GCC CAT GGG CTG GAG GTG GAG CCC TCA GCC CTG  
 A Y A A T K A A R A H G L E V E P S A L 488  
 452 461  
 497 GAA CAA GGC TTC AGG CAG GCA TAC AGG GCT CAG AGC CAC AGC TTC CCC AAC TAC  
 E Q G F R Q A Y R A Q S H S F P N Y 542  
 506 515  
 551 GGC CTG AGC CAC GGC CTA ACC TCC CGC CAG TGG TGG CTG GAT GTG CTC CTG CAG  
 G L S H G L T T S R Q W L D V V L Q 596  
 605 614  
 ACC TTC CAC CTG GCG GGT GTC CAG GAT GCT CAG GCT GTA GCC CCC ATC GCT GAA  
 T F H L A G G D A Q A V A P I A E 650  
 659 668  
 CAG CTT TAT AAA GAC TTC AGC CAC CCC TGC ACC TGG CAG GTG GTG GAT GGG GCT  
 Q L Y K D F S H P C T W Q V L D G A 704  
 713 722 731 740 749 758  
 GAG GAC ACC CTG AGG GAG TGC CGC ACA CGG GGT CTG AGA CTG GCA GTG ATC TCC  
 E D T L R E C R T R G L R L A A V I S

FIGURE 1B



767 AAC TTT GAC CGA CGG CTA GAG GGC ATC CTG GGG GGC CTT GGC CTG 803 812  
 N F D R R L E G I L L G G L R E H  
 821 TTC GAC TTT GTG CTG ACC TCC GAG GCT GCT GGC TGG CCC AAG CCG GAC CCC CGC 866  
 F D F V L T S E A A G W P K P D P R  
 875 ATT TTC CAG GAG GCC TTG CGG CTT GCT CAT ATG GAA CCA GTA GTG GCA GCC CAT 920  
 I F Q E A L L R L A H M E P V A A H  
 929 GTT GGG GAT AAT TAC CTC TGC GAT TAC CAG GGC CCT CGG GCT GTG GGC ATG CAC 974  
 V G D N Y L C D Y Q G P R A V G M H  
 983 AGC TTC CTG GTG GTT GGC CCA CAG GCA CTG GAC CCC GTG GTC AGG GAT TCT GTA 1028  
 S F L V V G G P Q A L D P V V R D S V  
 1037 CCT AAA GAA CAC ATC CTC CCC TCT CTG GCC CAT CTC CTG CCT GCC CTT GAC TGC 1082  
 P K E H I L L P S L A H L L L P A L D C  
 1091 CTA GAG GGC TCA ACT CCA GGC CTT TGA GGC CAG TGA GGG AAG TGG CTG GGC CCT 1136  
 L E G S T P G L

FIGURE 1C

1145 1154 1163 1172 1181 1190  
AGG CCA TGG AGA AAA CCT TAA ACA AAC CCT GGA GAC AGG GAG CCC CTT CTT TCT

1199 1208 1217 1226 1235 1244  
CCA CAG CTC TGG ACC TTT CCC CCT CTC CCT GCG GCC TTT GTC ACC TAC TGT GAT

1253 1262 1271 1280 1289  
AAT AAA GCA GTG AGT GCT GAG CTC TCA CCC TTC CCC CAC TAA AAA AAA AA 3'

FIGURE 1D

10 19 28 37 46 55  
 5' CCA CGC GTC CGG TTC CGT TCA ACG AAG TGG TTG CTT TTT TTA GTT CCG GCA ATG  
 M  
 64 73 82 91 100 109  
 AGT TGC GCC GCG GCG GGT CCC CGC CTT TGG CGG CTG CGC CCA GGG GCC  
 S C A G A A A P R L R P G A  
 118 127 136 145 154 163  
 CGG CGG TCC CTC TCA GCT TAT GGA AGA ACC AGT GTC AGA TTT CGC AGT TCA  
 R R S L S A Y G R R T S V R F R S S  
 172 181 190 199 208 217  
 GGA ATG ACT TTA GAC AAT ATC AGT CGG GCA GCT GTG GAT CGA ATA ATC CGG GTG  
 G M T L D N I S R A A V D R I I R V  
 226 235 244 253 262 271  
 GAT CAT GCA GGC GAA TAT GGA GCA AAC CGC ATC TAT GCC GGG CAG ATG GCT GTC  
 D H A G E Y G A N R I Y A G Q M A V  
 280 289 298 307 316 325  
 CTG GGT CGG ACC AGC GTC GCG CCA GTC ATT CAG AAA ATG TGG GAT CAA GAA AAG  
 L G R T S V G P V I Q K M W D Q E K  
 334 343 352 361 370 379  
 GAC CAT TTG AAA AAG TTC AAT GAG TTG ATG GTT ATG TTC AGG GTC CGG CCA ACA  
 D H L K K AAG TTC AAT GAG TTG ATG GTT ATG TTC AGG GTC CGG CCA ACA  
 T

FIGURE 2A

388 GTT CTG ATG CCC TTG TGG AAC GTG CTG GGG TTT GCA CTG GCG GCG ACC GCC 433  
 V L M P L L W N V L L G F A L G A G T A  
 442 TTG CTC GGG AAG GAA GGT GCC ATG GCC TGC ACC GTG GCG GTG GAA GAG AGC ATA 487  
 L L G K E G A M A C T V A V E E S I  
 496 GCA CAT CAC TAC AAC AAC CAG ATC AGG ACG CTG ATG GAG GAG GAC CCT GAA AAA 541  
 A H Y N N Q I R T L M E E D P E K  
 550 TAC GAG GAA CTT CTT CAG CTG ATA AAG AAA TTT CGG GAT GAA GAG CTT GAG CAC 595  
 Y E E L L Q L I K K F R D E E L E H  
 604 CAT GAC ATA GGC CTC GAC CAT GAT GCA GAA TTG GCT CCA GCC TAT GCC GTC CTG 649  
 H D I G L D H D A E L A P A Y A V L  
 658 AAG AGC ATT ATC CAG GCC GGA TGC AGA GTG GCG ATA TAT TTA TCA GAA AGA TTA 703  
 K S I I Q A G C R V A I Y L S E R L  
 712 TAA AGT GTG TCC AGT TTT GCC TGT CTA TAA AAG ATG ATA GTA ATT TAC CAA GTG 757

FIGURE 2B

766 775 784 793 802 811  
ACA TTT GCA GAG AAG CAG GTG TAC AGT TAT CGT TGT ACT TTT GTA CAA TGT GAA

820 829 838 847 856 865  
TTT TGT TAA TAA ATT ATA AGG TTT GTT TTT TTT TTA AAC TCT GCA GTG TTG

874 883 892 901 910 919  
ATT TTT CTC TGG GTT GTT TTT TCT GCC ATG AGA CCA ACA GGT CAC CAG CCT TGT

928 937  
TCA AGT TAC AGC AAA CGA AGC TGG G 3'

FIGURE 2C

1 M S C A G A A - - - - - A A P R L W R L R P G A R R S L S 2267905  
 1 M S A A G A I - - - - - A A A S V G R L R T G V R R P F S 93415017  
 1 M A H R L Q I R L L T W D V K D T L L R L R H P L G E A Y A 1581473  
 1 M R S L S R F R L I T F D V T N T L L Q F R T T P G K Q Y G g1561732  
  
 25 A Y G R R T S V R F R S S G M T - - - - - L D N I S R A A V D R I 2267905  
 25 E Y G R G L I I R C H S S G M T - - - - - L D N I R A A V D R I 93415017  
 31 T K A R A H G L E V E P S A L E Q G F R Q A Y R A Q S H S F 1581473  
 31 E I G A L F G A R C D N N E L A K N F K A N W Y K M N R D Y g1561732  
  
 53 I R V D H A G E Y G A N R - - - - - I Y A G Q M A 2267905  
 53 I R V D H A G E Y G A N R - - - - - I Y A G Q M A 93415017  
 61 P N Y G - - L S H G L T S R Q W W L D V V L Q T F H L A G V 1581473  
 61 P N F G R D T N P Q M E W Q Q W W R K L I A G T F A E S G A g1561732  
  
 73 V L G R T S V G P V I Q K M - - - - - W D Q E K D H 2267905  
 73 V L G R T S V G P V I Q K M - - - - - W D Q E K N H 93415017  
 89 Q D A Q A - V A P I A E Q L Y K D F S H P C T W Q V L D G A 1581473  
 91 A I P D E K L H N F S N H L I E L Y K T S I C W Q P C N G S g1561732  
  
 94 L K K F N E - - - - - L M V M F R V R P T 2267905  
 94 L K K F N E - - - - - L M I A F R V R P T 93415017  
 118 E D T L R E C R T R G L R - - - - - L A V I S N F D R R L E 1581473  
 121 V E L L Q Q L R - K E L K P E K C K L G V I A N F D P R L P g1561732

FIGURE 3A

110 V L M P - - - L W N V L G F A L G A G T A L L G K E G A M A 2267905  
 110 V L M P - - - L W N V A G F A L G A G T A L L G K E G A M A g3415017  
 143 G I L G G L G L R E H F D F V L T S E A A G W P K P D P R I 1581473  
 150 T L Q N T K L D Q Y L D F A I N S Y E V Q A E K P D P Q I g1561732  
  
 137 C T V A V E E S I A H H Y N N Q I R T L M E E D P E - K Y - 2267905  
 137 C T V A V E E S I A H H Y N N Q I R M L M E E D P E - K Y - g3415017  
 173 F Q E A L R - - - L A H M E P V V A A H V G D N Y L C D Y Q 1581473  
 180 F Q K A M E K S G L K N L K P E E C L H I G D G P T T D Y L g1561732  
  
 165 - - - - - E E L L Q L I K K F R D E E L E H H D I G L D 2267905  
 165 - - - - - E E L L Q V I K Q F R D E E L E H H D T G L D g3415017  
 200 G P R A V G M H S F L V V G P Q A L D P V V R - - - D S V P 1581473  
 210 A A K E L G W H S A L V H E - K S Y A Y L V K K Y G E D I D g1561732  
  
 188 H D A E L A P A Y A V L K S I I Q A G C R V A I Y L S E R L 2267905  
 188 H D A E L A P A Y A L L K R I I Q A G C S A A I Y L S E R F g3415017  
 227 K E H I L P S L A H L L P A L - - - D C L E G S - - T P G L 1581473  
 239 R D H V F P S L Y D F H K - - - - - I S D G - - A V V W g1561732

FIGURE 3B

Docket No.: PF-0659 USN

**DECLARATION AND POWER OF ATTORNEY FOR  
UNITED STATES PATENT APPLICATION**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name, and

I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if more than one name is listed below) of the subject matter which is claimed and for which a United States patent is sought on the invention entitled

**PROTEINS ASSOCIATED WITH CIRCADIAN RHYTHMS**

the specification of which:

   / is attached hereto.

  X   / was filed on (to be assigned), as application Serial No. 09/889,236 and if this box contains an X    /, was amended on \_\_\_\_\_.

  X   / was filed as Patent Cooperation Treaty international application No. PCT/US00/01086 on January 14, 2000, if this box contains an X    /, was amended on under Patent Cooperation Treaty Article 19 on \_\_\_\_\_ 2002, and if this box contains an X    /, was amended on \_\_\_\_\_.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge my duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim the benefit under Title 35, United States Code, §119 or §365(a)-(b) of any foreign application(s) for patent or inventor's certificate indicated below and of any Patent Cooperation Treaty international applications(s) designating at least one country other than the United States indicated below and have also identified below any foreign application(s) for patent or inventor's certificate and Patent Cooperation Treaty international application(s) designating at least one country other than the United States for the same subject matter and having a filing date before that of the application for said subject matter the priority of which is claimed:



**Docket No.: PF-0659 USN**

Country	Number	Filing Date	Priority Claimed
_____	_____	_____	// Yes // No
_____	_____	_____	// Yes // No

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below.

Application Serial No.	Filed	Status (Pending, Abandoned, Patented)
60/183,019	January 15, 1999	Expired

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in said prior application(s) in the manner required by the first paragraph of Title 35, United States Code §112, I acknowledge my duty to disclose material information as defined in Title 37 Code of Federal Regulations, §1.56(a) which occurred between the filing date(s) of the prior application(s) and the national or Patent Cooperation Treaty international filing date of this application:

Application Serial No.	Filed	Status (Pending, Abandoned, Patented)
_____	_____	_____

I hereby appoint the following:

Lucy J. Billings	Reg. No. <u>36,749</u>
Michael C. Cerrone	Reg. No. <u>39,132</u>
Diana Hamlet-Cox	Reg. No. <u>33,302</u>
Richard C. Ekstrom	Reg. No. <u>37,027</u>
Barrie D. Greene	Reg. No. <u>46,740</u>
Lynn E. Murry	Reg. No. <u>42,918</u>
Shirley A. Recipon	Reg. No. <u>47,016</u>
Susan K. Sather	Reg. No. <u>44,316</u>
Michelle M. Stempien	Reg. No. <u>41,327</u>
David G. Streeter	Reg. No. <u>43,168</u>
P. Ben Wang	Reg. No. <u>41,420</u>

respectively and individually, as my patent attorneys and/or agents, with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith. Please address all communications to:

Docket No.: PF-0659 USN

**LEGAL DEPARTMENT**  
**INCYTE GENOMICS, INC.**  
**3160 PORTER DRIVE, PALO ALTO, CA 94304**

TEL: 650-855-0555 FAX: 650-849-8886 or 650-845-4166

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.


**First Joint Inventor:**

100

Full name:

Jennifer L. Hillman

Signature:



Date:

September 21, 2001

Citizenship:

United States

Residence:

Mountain View, California<sup>CA</sup>

P.O. Address:

230 Monroe Drive, #17  
Mountain View, California 94040**Second Joint Inventor:**

200

Full name:

Y. Tom Tang

Signature:



Date:

Sept. 10, 2001

Citizenship:

United States

Residence:


San Jose, California<sup>CA</sup>

P.O. Address:


4230 Ranwick Court  
San Jose, California 95118

Docket No.: PF-0659 USN

## Third Joint Inventor:

300 Full name: Dyung Aina M. Lu  
Signature:   
Date: Sept 7, 2001  
Citizenship: United States  
Residence: CA  
San Jose, California  
P.O. Address: 233 Coy Drive  
San Jose, California 95123

## Fourth Joint Inventor:

400 Full name: Yalda Azimzai  
Signature:   
Date: September 13, 2001  
Citizenship: United States  
Residence: CA  
Castro Valley, California  
P.O. Address: 5518 Boulder Canyon Drive  
Castro Valley, California 94552

WO 00/42172

PCT/US00/01086

## SEQUENCE LISTING

<110> INCYTE PHARMACEUTICALS, INC.  
 HILLMAN, Jennifer L.  
 TANG, Y. Tom  
 LU, Dyung Aina M.  
 AZIMZAI, Yalda

<120> PROTEINS ASSOCIATED WITH CIRCADIAN RHYTHMS

<130> PF-0659 PCT

<140> To Be Assigned  
 <141> Herewith

<150> 09/231,160; unassigned  
 <151> 1999-01-15

<160> 6

<170> PERL Program

<210> 1  
 <211> 251  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 1581473CD1

<400> 1  
 Met Ala His Arg Leu Gln Ile Arg Leu Leu Thr Trp Asp Val Lys  
 1 5 10 15  
 Asp Thr Leu Leu Arg Leu Arg His Pro Leu Gly Glu Ala Tyr Ala  
 20 25 30  
 Thr Lys Ala Arg Ala His Gly Leu Glu Val Glu Pro Ser Ala Leu  
 35 40 45  
 Glu Gln Gly Phe Arg Gln Ala Tyr Arg Ala Gln Ser His Ser Phe  
 50 55 60  
 Pro Asn Tyr Gly Leu Ser His Gly Leu Thr Ser Arg Gln Trp Trp  
 65 70 75  
 Leu Asp Val Val Leu Gln Thr Phe His Leu Ala Gly Val Gln Asp  
 80 85 90  
 Ala Gln Ala Val Ala Pro Ile Ala Glu Gln Leu Tyr Lys Asp Phe  
 95 100 105  
 Ser His Pro Cys Thr Trp Gln Val Leu Asp Gly Ala Glu Asp Thr  
 110 115 120  
 Leu Arg Glu Cys Arg Thr Arg Gly Leu Arg Leu Ala Val Ile Ser  
 125 130 135  
 Asn Phe Asp Arg Arg Leu Glu Gly Ile Leu Gly Gly Leu Gly Leu  
 140 145 150  
 Arg Glu His Phe Asp Phe Val Leu Thr Ser Glu Ala Ala Gly Trp  
 155 160 165

WO 00/42172

PCT/US00/01086

Pro Lys Pro Asp	Pro Arg Ile Phe Gln Glu Ala Leu Arg Leu Ala	
	170	175 180
His Met Glu Pro Val Val Ala Ala His Val Gly Asp Asn Tyr Leu		
	185	190 195
Cys Asp Tyr Gln Gly Pro Arg Ala Val Gly Met His Ser Phe Leu		
	200	205 210
Val Val Gly Pro Gln Ala Leu Asp Pro Val Val Arg Asp Ser Val		
	215	220 225
Pro Lys Glu His Ile Leu Pro Ser Leu Ala His Leu Leu Pro Ala		
	230	235 240
Leu Asp Cys Leu Glu Gly Ser Thr Pro Gly Leu		
	245	250

&lt;210&gt; 2

&lt;211&gt; 217

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 2267905CD1

&lt;400&gt; 2

Met Ser Cys Ala Gly Ala Ala Ala Ala Pro Arg Leu Trp Arg Leu	
1 5	10 15
Arg Pro Gly Ala Arg Arg Ser Leu Ser Ala Tyr Gly Arg Arg Thr	
20 25	30
Ser Val Arg Phe Arg Ser Ser Gly Met Thr Leu Asp Asn Ile Ser	
35 40	45
Arg Ala Ala Val Asp Arg Ile Ile Arg Val Asp His Ala Gly Glu	
50 55	60
Tyr Gly Ala Asn Arg Ile Tyr Ala Gly Gln Met Ala Val Leu Gly	
65 70	75
Arg Thr Ser Val Gly Pro Val Ile Gln Lys Met Trp Asp Gln Glu	
80 85	90
Lys Asp His Leu Lys Lys Phe Asn Glu Leu Met Val Met Phe Arg	
95 100	105
Val Arg Pro Thr Val Leu Met Pro Leu Trp Asn Val Leu Gly Phe	
110 115	120
Ala Leu Gly Ala Gly Thr Ala Leu Leu Gly Lys Glu Gly Ala Met	
125 130	135
Ala Cys Thr Val Ala Val Glu Glu Ser Ile Ala His His Tyr Asn	
140 145	150
Asn Gln Ile Arg Thr Leu Met Glu Glu Asp Pro Glu Lys Tyr Glu	
155 160	165
Glu Leu Leu Gln Leu Ile Lys Lys Phe Arg Asp Glu Glu Leu Glu	
170 175	180
His His Asp Ile Gly Leu Asp His Asp Ala Glu Leu Ala Pro Ala	
185 190	195
Tyr Ala Val Leu Lys Ser Ile Ile Gln Ala Gly Cys Arg Val Ala	
200 205	210
Ile Tyr Leu Ser Glu Arg Leu	
215	

WO 00/42172

PCT/US00/01086

<210> 3  
 <211> 1294  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 1581473CB1

<400> 3  
 ttctgcgtca ggtccgggct cctggacttc gcctttcccg agccctggag gtggggagaa 60  
 aaggttcacc aatttttaaa atccaaatat atctcatggt acagtggaag aactggccag 120  
 agagtctgga agtttggtt ctggtcctgg ctgtgccact gactcactgt gaccttggga 180  
 tcttggtgctg tgaagacatt tccaagtgc ttcatgttag ccagcaaatac tgaccacaaa 240  
 ggcttggaag gaggtgattg ttaggttgcg cagaggtggt cttatccagc tcagcttccc 300  
 ctgggaccca ccgtgggacc tgaggcagaa ctggggtgga cttggcctcc tccatggcac 360  
 accggctgca gatacgactg ctgacgtggg atgtgaagga cacgctgctc aggctccgcc 420  
 accccttagg ggaggcctat gccaccaagg cccgggcccc tgggctggag gtggagccct 480  
 cagccctgga acaaggcttc aggcaggcat acagggtcca gagccacagc ttccccaact 540  
 acggcctgag ccacggccta acctcccgcc agtgggtggt ggatgtggtc ctgcagacct 600  
 tccacctggc ggggtgtccag gatgctcagg ctgtagcccc catcgtgaa cagctttata 660  
 aagacttcag ccacctctgc acctggcagg tgttggtggt ggctgaggac accctgaggg 720  
 agtgccgcac acggggtctg agactggcag tgatctccaa ctttgaccga cggctagagg 780  
 gcacctggtg gggccttggc ctgctgaac acttcgactt tgtgctgacc tccgaggctg 840  
 ctggctggcc caagccggac cccgcattt tccaggaggc cttgcggctt gctcatatgg 900  
 aaccagtagt ggcagcccat gttggggata attacctctg cgattaccag gggcctcggg 960  
 ctgtgggcat gcacagcttc ctggtggttg gccacaggc actggacccc gtggtcaggg 1020  
 attctgtacc taaagaacac atcctccctt ctctggccca tctcctgctt gcccttgact 1080  
 gcctagaggg ctcaactcca gggctttgag gccagtggag gaagtggctg ggccctaggc 1140  
 catggagaaa accttaaa aacctggag acaggagacc ccttctttct ccacagctct 1200  
 ggacctttcc cctctccct gcggcctttg tcacctactg tgataataaa gcagtgagt 1260  
 ctgagctctc accttcccc cactaaaaaa aaaa 1294

<210> 4  
 <211> 944  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 2267905CB1

<400> 4  
 cccacgcgtc cggttccgtt caacgaagtg gttgctttt ttagttccgg caatgagttg 60  
 cgccggggcg gcggcggtc cccgcctttg gcggtgctc ccaggggccc ggcggtccct 120  
 ctgagcttat ggaagaagaa ccagtgtcag atttcgcagt tcaggaatga ctttagacaa 180  
 tatcagtcgg gcagctgtgg atcgaataat cggggtggat catgcaggcg aatatggagc 240  
 aaaccgcata tatgccgggc agatggctgt cctgggtcgg accagcgtcg ggccagtcac 300  
 tcagaaaatg tgggatcaag aaaaggacca tttgaaaaag ttcaatgagt tgatggttat 360  
 gttcagggtc cggccaacag ttctgatgcc cttgtggaac gtgctggggg ttgcaactgg 420  
 ggccggggacc gccttgctcg ggaagggaag tgccatggcc tgaccctgg cggtggaaga 480  
 gagcatagca catcactaca acaaccagat caggacgctg atggaggagg acctgaaaa 540  
 atacaggaa cttcttcagc tgataaagaa atttcgggat gaagagcttg agcaccatga 600  
 cataggcctc gaccatgatg cagaattggc tccagcctat gccgtcctga agagcattat 660

WO 00/42172

PCT/US00/01086

```

ccaggccgga tgcagagtgg cgatatatatt atcagaaaaga ttataaagtg tgtccagttt 720
tgcctgtcta taaaagatga tagtaattta ccaagtgaca tttgcagaga aacaggtgta 780
cagttatcgt tgtacttttg tacaatgtga attttggtta taaattataa ggtttgtttt 840
ttttttttta aactctgcag tgttgatttt tctctgggtt gttttttctg ccatgagacc 900
aacaggtcac cagccttggt caagttacag caaacgaagc tggg 944

```

&lt;210&gt; 5

&lt;211&gt; 260

&lt;212&gt; PRT

<213> *Drosophila melanogaster*

&lt;300&gt;

&lt;308&gt; GenBank ID No: g1561732

&lt;400&gt; 5

Met	Arg	Ser	Leu	Ser	Arg	Phe	Arg	Leu	Ile	Thr	Phe	Asp	Val	Thr	
1				5					10					15	
Asn	Thr	Leu	Leu	Gln	Phe	Arg	Thr	Thr	Pro	Gly	Lys	Gln	Tyr	Gly	
				20					25					30	
Glu	Ile	Gly	Ala	Leu	Phe	Gly	Ala	Arg	Cys	Asp	Asn	Asn	Glu	Leu	
				35					40					45	
Ala	Lys	Asn	Phe	Lys	Ala	Asn	Trp	Tyr	Lys	Met	Asn	Arg	Asp	Tyr	
				50					55					60	
Pro	Asn	Phe	Gly	Arg	Asp	Thr	Asn	Pro	Gln	Met	Glu	Trp	Gln	Gln	
				65					70					75	
Trp	Trp	Arg	Lys	Leu	Ile	Ala	Gly	Thr	Phe	Ala	Glu	Ser	Gly	Ala	
				80					85					90	
Ala	Ile	Pro	Asp	Glu	Lys	Leu	His	Asn	Phe	Ser	Asn	His	Leu	Ile	
				95					100					105	
Glu	Leu	Tyr	Lys	Thr	Ser	Ile	Cys	Trp	Gln	Pro	Cys	Asn	Gly	Ser	
				110					115					120	
Val	Glu	Leu	Leu	Gln	Gln	Leu	Arg	Lys	Glu	Leu	Lys	Pro	Glu	Lys	
				125					130					135	
Cys	Lys	Leu	Gly	Val	Ile	Ala	Asn	Phe	Asp	Pro	Arg	Leu	Pro	Thr	
				140					145					150	
Leu	Leu	Gln	Asn	Thr	Lys	Leu	Asp	Gln	Tyr	Leu	Asp	Phe	Ala	Ile	
				155					160					165	
Asn	Ser	Tyr	Glu	Val	Gln	Ala	Glu	Lys	Pro	Asp	Pro	Gln	Ile	Phe	
				170					175					180	
Gln	Lys	Ala	Met	Glu	Lys	Ser	Gly	Leu	Lys	Asn	Leu	Lys	Pro	Glu	
				185					190					195	
Glu	Cys	Leu	His	Ile	Gly	Asp	Gly	Pro	Thr	Thr	Asp	Tyr	Leu	Ala	
				200					205					210	
Ala	Lys	Glu	Leu	Gly	Trp	His	Ser	Ala	Leu	Val	His	Glu	Lys	Ser	
				215					220					225	
Tyr	Ala	Tyr	Leu	Val	Lys	Lys	Tyr	Gly	Glu	Asp	Ile	Asp	Arg	Asp	
				230					235					240	
His	Val	Phe	Pro	Ser	Leu	Tyr	Asp	Phe	His	Lys	Lys	Ile	Ser	Asp	
				245					250					255	
Gly	Ala	Val	Val	Trp											
				260											

WO 00/42172

PCT/US00/01086

<210> 6  
 <211> 217  
 <212> PRT  
 <213> Mus musculus

<300>  
 <308> GenBank ID No: g3415017

<400> 6  
 Met Ser Ala Ala Gly Ala Ile Ala Ala Ala Ser Val Gly Arg Leu  
   1                  5                  10                  15  
 Arg Thr Gly Val Arg Arg Pro Phe Ser Glu Tyr Gly Arg Gly Leu  
                   20                  25                  30  
 Ile Ile Arg Cys His Ser Ser Gly Met Thr Leu Asp Asn Ile Asn  
                   35                  40                  45  
 Arg Ala Ala Val Asp Arg Ile Ile Arg Val Asp His Ala Gly Glu  
                   50                  55                  60  
 Tyr Gly Ala Asn Arg Ile Tyr Ala Gly Gln Met Ala Val Leu Gly  
                   65                  70                  75  
 Arg Thr Ser Val Gly Pro Val Ile Gln Lys Met Trp Asp Gln Glu  
                   80                  85                  90  
 Lys Asn His Leu Lys Lys Phe Asn Glu Leu Met Ile Ala Phe Arg  
                   95                  100                 105  
 Val Arg Pro Thr Val Leu Met Pro Leu Trp Asn Val Ala Gly Phe  
                  110                 115                 120  
 Ala Leu Gly Ala Gly Thr Ala Leu Leu Gly Lys Glu Gly Ala Met  
                  125                 130                 135  
 Ala Cys Thr Val Ala Val Glu Glu Ser Ile Ala Asn His Tyr Asn  
                  140                 145                 150  
 Asn Gln Ile Arg Met Leu Met Glu Glu Asp Pro Glu Lys Tyr Glu  
                  155                 160                 165  
 Glu Leu Leu Gln Val Ile Lys Gln Phe Arg Asp Glu Glu Leu Glu  
                  170                 175                 180  
 His His Asp Thr Gly Leu Asp His Asp Ala Glu Leu Ala Pro Ala  
                  185                 190                 195  
 Tyr Ala Leu Leu Lys Arg Ile Ile Gln Ala Gly Cys Ser Ala Ala  
                  200                 205                 210  
 Ile Tyr Leu Ser Glu Arg Phe  
                  215